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Abstract 
Chronic alcohol misuse or alcohol use disorder is a common problem worldwide. 
Excessive alcohol consumption can affect almost every organ in the body but 
neurological complications can occur due to acute intoxicating effects as well as 
longer term damage known as alcohol-related brain damage. The cognitive 
impairments associated with chronic alcohol misuse can be compounded by 
associated liver damage leading to an increase in circulating neurotoxic substances 
such as ammonia giving rise to a condition known as hepatic encephalopathy. The 
pathogenesis of hepatic encephalopathy is currently unknown however animal 
models of alcohol misuse suggest that aberrant cell proliferation attributed to 
neurogenesis may play a role. 
  
Neurogenesis occurs in the adult mammalian brain in two neurogenic niches the 
subventricular zone lining the lateral ventricles and the subgranular zone of the 
hippocampus and involves the proliferation of a neural stem cell and eventual 
integration of an immature neuron into the existing circuitry. Although this process 
has been widely proven in animals its existence in humans remains 
controversial. So, prior to addressing a role for neurogenesis in disease its existence 
needs to be proven in normal individuals. Here, cell proliferation and neurogenesis 
were simultaneously examined in the subventricular zone and subgranular zone of 
23 individuals aged 0.2-59 years, using immunohistochemistry and 
immunofluorescence in combination with unbiased stereology. This demonstrated 
a marked decline in proliferating cells in both the subventricular zone and 
subgranular zone in early infancy such that the levels of proliferation were similar 
 v 
to the adjacent parenchyma by four and one years, respectively. Furthermore, the 
phenotype of proliferating cells changed with age such that in the adult 
subventricular zone and subgranular zone, and adjacent parenchyma, all 
proliferating cells co-localised with the microglial marker, Iba1. Taken together this 
suggests that adult neurogenesis is a residual process and that any potential 
disease-related alterations in proliferation in the adult brain are likely associated 
with microglia. 
  
Indeed, widespread proliferating cells that co-localised with the microglial marker 
Iba1 were found in a subset of chronic alcoholics with a pathological diagnosis of 
HE. In contrast cases without microglial proliferation displayed microglial dystrophy 
and associated neuronal loss in the prefrontal cortex. There were no obvious 
differences between these subsets from the clinical and pathological data available. 
  
To determine the cause and pathogenic significance of this microglial proliferation, 
a pilot study was conducted to develop an animal model of chronic hepatic 
encephalopathy using the hepatotoxin, thioacetamide and combinations of known 
risk factors for hepatic encephalopathy; chronic alcohol use and a high-fat diet. 
Animals receiving thioacetamide had macroscopic evidence of liver injury, 
elevations of transaminases and associated anxiety-like behaviour measured in an 
open-field test. There were however no associated microglial or astrocytic changes 
in these animals and combinations of alcohol and high-fat diet had no additional 
effects. 
  
 vi 
In conclusion, this work has shown that the majority of the rare proliferative events 
in the adult human brain are microglia. Chronic alcoholism with a pathological 
diagnosis of hepatic encephalopathy results in shifts in microglial phenotype with 
one subset of patients demonstrating proliferation and another dystrophy. Future 
work is required to develop an animal model of chronic hepatic encephalopathy, 
where the role of microglial dysfunction in hepatic encephalopathy pathogenesis 
can be further elucidated. 
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Introduction 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1 Alcohol 
 
1.1.1 Alcohol Use Disorders 
Alcohol misuse is the third largest contributor to disease burden worldwide 
accounting for 3.3 million deaths annually and 5.1% of all disability adjusted life 
years (DALYs) globally (World Health Organisation, 2011). Alcohol poses a 
significant problem in the community with 22.1% of Australians having suffered 
from an alcohol use disorder (AUD) in their lifetime and 3.9% of individuals meeting 
the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria of 
alcohol dependence in the previous 12 months (Teesson et al., 2010). Furthermore, 
these household-based studies do not account for the homeless population who 
have significantly higher incidences of alcohol dependence both in Australia 
(Teesson et al., 2003) and internationally (Fazel et al., 2008). 
 
Previously regarded as two separate disorders in DSM-IV: alcohol abuse and alcohol 
dependence, these are now treated as one entity known as AUDs with varying 
severities of mild, moderate and severe according to the criteria in DSM-V 
(American Psychiatric Association, 2013). AUDs represent a vast array of symptoms 
due to the alcohol’s effect on nearly all organ systems. AUDs can lead to a variety of 
severe complications including pancreatitis (Lowenfels et al., 1994), 
cardiomyopathy (Guzzo-Merello et al., 2014), portal hypertension, oesophageal 
varices and gastrointestinal bleeds (Cremers and Ribeiro, 2014) as well as being a 
risk factor for a large number of other conditions (Mansoori and Jain, 2015, Prabhu 
et al., 2014). The most common complication in AUDs is liver disease, which begins 
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as reversible steatohepatitis but can progress to irreversible cirrhosis (Bruha et al., 
2012, Mann et al., 2003). This liver disease can lead to the serious neurological 
complication of hepatic encephalopathy (HE). 
 
Of course, the most pronounced of symptom of AUDs is the neurological effects 
resulting from acute intoxication including increased risk taking behaviour, 
impaired cognition, short-term memory loss, sexual dysfunction and in severe cases 
toxicity. Whilst the acute effects of alcohol misuse are widely recognised, the 
consequences of long-term use on the brain are less so. 
 
1.1.2 Alcohol-Related Brain Damage 
 
Chronic exposure to large amounts of alcohol can lead to alcohol-related brain 
damage (ARBD), arising due to the direct toxic effects of alcohol on the brain. This 
presents clinically as impaired working memory (Pfefferbaum et al., 2001), 
cognitive dysfunction (Green et al., 2010), attention deficits and loss of smell 
sensation (Rupp et al., 2003). Pathological features of ARBD include white matter 
(WM) atrophy (Harper et al., 1988) and regional neuronal loss (Kril et al., 1997b). 
The mechanisms behind these changes in ARBD is complicated by the fact that 
chronic alcoholics often have many other co-morbid conditions, co-substance abuse 
such as cigarette smoking (McCorkindale et al., 2016), along with nutritional 
deficiencies and liver disease as a consequence of alcohol’s global effects 
(Butterworth, 1995, Kril, 1995). 
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The pathogenesis of ARBD is currently not understood, particularly the pattern of 
neuron loss. Some groups have proposed that alterations in adult neurogenesis, a 
process whereby new neurons are generated, is involved (Geil et al., 2014). Animal 
models have shown reversible decreases of neurogenesis in the hippocampus 
(Herrera et al., 2003, Nixon and Crews, 2004) and irreversible deficits in the 
subventricular zone (SVZ) (Hansson et al., 2010). Importantly however these studies 
are in animal models and adult neurogenesis, or at least its functional role, is less 
well understood in humans. 
 
1.2 Neurogenesis 
 
The longstanding dogma in neuroscience has been that the mammalian central 
nervous system (CNS) is a post-mitotic organ (Allen, 1912). This was overturned 
when Joseph Altman used thymidine-H3 to label proliferating granule cells within 
the hippocampus of rats (Altman and Das, 1965). This seminal study eventually led 
to an explosion of research in the area of adult neurogenesis, driven by the 
enormous therapeutic potential for neurodegenerative disease (Eriksson et al., 
1998). 
 
1.2.1 The origins of adult neurogenesis 
The vast majority of neurogenesis occurs during the embryonic period in humans. 
The nervous system arises from the neuroectoderm with massive proliferation from 
neural progenitor cells within the ventricular zone surrounding the neural tube. This 
begins around embryonic day 25 with symmetrical division of neural progenitor 
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cells to expand this population, at day 42 there is a switch to asymmetrical division, 
producing one progenitor cell and one neuroblast, an immature neuron (Stiles and 
Jernigan, 2010). The neuroblasts undergo radial migration and differentiation and 
potentially integration. This process continues to embryonic day 108 at which point 
cortical neurogenesis is complete in humans (Clancy et al., 2001). Neurons are 
produced in excess during gestation and following this massive expansion, a second 
process involving widespread neuronal apoptosis occurs which can be as high as 
70% of neurons in some layers of the cortex (Rabinowicz et al., 1996). This 
programmed cell death begins around gestational week six, coincides with the 
appearance of microglial cells and is completed in the prenatal period (Rakic and 
Zecevic, 2000, Stiles and Jernigan, 2010). Whilst significant synaptic pruning 
continues in the postnatal period, neurogenesis is largely complete prior to birth 
with the exception of two recently discovered neurogenic niches, the SVZ and the 
subgranular zone (SGZ) of the hippocampus. 
 
1.2.2 The Subventricular Zone 
 
The SVZ is a laminar structure with cells at differing stages of maturation 
throughout (Ihrie and Alvarez-Buylla, 2011, Curtis et al., 2005b, Quinones-Hinojosa 
et al., 2006, Doetsch et al., 1997). Anatomically, the SVZ is divided into four layers; a 
layer of ependymal cells lining the lateral ventricle (Layer I), a hypocellular layer 
immediately underlying the ependymal layer (Layer II), an area of dense astrocyte 
cell bodies (Layer III) and the deepest layer adjacent to the caudate nucleus 
consisting of a thin layer of myelin (Layer IV) (Quinones-Hinojosa et al., 2006). 
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There are further functional divisions of the SVZ although most of these are 
extrapolated from animal studies (Doetsch et al., 1999, Doetsch et al., 1997). The 
main proliferative unit of the mammalian SVZ is the astrocyte-like type B cells 
(Doetsch et al., 1999). These are also termed the neural stem cells and divide slowly 
(and asymmetrically) to produce transit-amplifier type C cells. Type B cells are 
further subdivided based on their location in the SVZ with B1 cells closely 
associated with the ependyma and extending a single cilium into the cerebrospinal 
fluid (CSF) whilst B2 cells are deeper in the SVZ towards the myelin layer. Type C 
cells divide rapidly, expanding the population, and some will differentiate into type 
A cells or neuroblasts that tangentially migrate within an astrocytic sheath (Curtis et 
al., 2005a, Curtis et al., 2005b, Doetsch et al., 1999, Doetsch et al., 1997). 
 
From the SVZ, newborn neurons migrate to the olfactory bulbs (OB) via the rostral 
migratory stream (RMS). In lower mammals, chains of migrating neurons project 
through the forebrain and integrate as interneurons into the granule cell layer 
(GCL) of the OB (Doetsch and Alvarez-Buylla, 1996, Lois and Alvarez-Buylla, 1994). 
These neurons can then become functionally integrated in the existing neural 
network of the OB and are thought to contribute to odour discrimination (Enwere 
et al., 2004, Sawamoto et al., 2011). The existence of the RMS in humans remains 
controversial and is discussed further in section 1.2.5 (Curtis et al., 2007b, Sanai et 
al., 2011). 
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1.2.3 The Subgranular Zone 
 
The hippocampus is a bilateral structure located in the medial temporal lobe and an 
integral part of the limbic system. Initially named by Julius Caesar Aranzi in 1587 
due to its resemblance to a seahorse (Bir et al., 2015), a more encompassing term 
when referring to the entire region is the hippocampal formation (Schultz and 
Engelhardt, 2014). The characteristic feature of the hippocampal formation is a 
ribbon of densely clustered pyramidal neurons termed the cornu ammonis (CA) 
which can be divided into four sections, the most medial part of the CA is termed 
the CA4 region and immediately below this but separate lies the dentate gyrus 
(DG). It was within this DG of rats where Joseph Altman first described the presence 
of cell proliferation in the adult brain (Altman, 1963). Further work demonstrated 
that this proliferation was restricted to the GCL of the DG, an area that became 
known as the SGZ, with no proliferation occurring throughout the CA or hilus 
(Altman and Bayer, 1990, Altman and Das, 1965). 
 
The process of neurogenesis within the SGZ of lower animals is similar but not 
identical to the SVZ. The stem cells of the SGZ are specialised radial astrocytes 
known as type-1 cells, morphologically differentiated from other astrocytes by a 
large cell body and a radial process projecting through the GCL and ramifying within 
the molecular layer (Filippov et al., 2003, Fukuda et al., 2003, Seri et al., 2004, Seri 
et al., 2001). These slowly dividing type-1 cells give rise to a rapidly dividing transit 
amplifier population, initially labelled D-cells (Seri et al., 2004, Seri et al., 2001) but 
more commonly referred to as type-2a and type-2b based on their expression of 
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doublecortin (DCX) or lack thereof. Finally, these type-2b cells give rise to type-3 
cells that are considered immature neurons (or neuroblasts) and have the potential 
to become integrated as a newborn granule cell in the GCL (Jones et al., 2003, Toni 
et al., 2007). 
 
The process of neurogenesis involves the proliferation, migration and functional 
integration within existing circuits. Endogenous markers across these stages, 
singularly or in combination, have been used to study and quantify adult 
neurogenesis. 
 
1.2.4 Stages of neurogenesis 
 
 
1.2.4.1 Proliferation 
 
The first stage of adult neurogenesis is the proliferation of neuronal precursor cells. 
Neural stem cells undergo asymmetrical division giving rise to an identical neural 
stem cell and one fate-restricted transit amplifier cell that divides rapidly. 
Accordingly, markers of proliferation can be used in the SGZ as probable indicators 
of neurogenesis. 
 
The most commonly used exogenous marker of proliferation in animal studies is 5-
Bromo-2’deoxyuridine (BrdU), a synthetic analogue of thymidine that is 
incorporated into DNA during cell proliferation and can be administered via 
injection (Taupin, 2007, Wojtowicz and Kee, 2006). Once incorporated into the DNA 
of dividing cells these cells can be stained using immunohistochemistry. The 
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advantage of using exogenous markers such as BrdU is they remain in the cell for its 
lifetime and co-labelling studies can be used to unambiguously determine the fate 
of a proliferating cell. Clearly this technique is not practical in human studies as 
injections during life are required. Although it was administered once to a group of 
patients as a cancer diagnostic agent and then used serendipitously to confirm SGZ 
cell proliferation (Bhardwaj et al., 2006, Eriksson et al., 1998, van den Berge et al., 
2010). Accordingly, endogenous markers of proliferation are required in the 
majority of neurogenesis studies.  
 
One of the most widely used endogenous markers is proliferating cell nuclear 
antigen (PCNA), a protein that acts as a sliding clamp for DNA polymerase- 
(Bowman et al., 2004). Although it is a widely-used marker, most notably by Curtis 
and colleagues to describe the RMS in humans (Curtis et al., 2007a), PCNA is 
problematic. Namely it has roles in DNA repair and transcription in addition to 
proliferation (Naryzhny, 2008) and interestingly there exists two “pools” of PCNA 
within mammalian cells: one involved in replication and a second soluble 
nucleoplasmic pool of unknown function (Zessin et al., 2016). Additionally, PCNA 
has consistently been shown to label the supposedly post-mitotic ependymal layer 
of the SVZ (Curtis et al., 2003, Curtis et al., 2005a, Sutherland et al., 2013, van den 
Berge et al., 2011). 
 
An alternative marker of proliferation is Ki67, widely considered the gold standard 
for tumour diagnostics in clinical pathology. Initially discovered in by researchers in 
Kiel, Germany and numbered by the original clone in their 96-well plate, Ki67 is a 
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unique protein with an unknown function  but expressed through all stages of the 
cell cycle except G0 (Scholzen and Gerdes, 2000). Ki67 undergoes redistribution in 
the nucleoplasm throughout different stages of the cell cycle (Bridger et al., 1998, 
Bruno et al., 1991, Kill, 1996) and importantly has not been shown to be involved in 
cellular processes other than proliferation. Other proliferative markers used include 
minichromosome maintenance protein 2 (Lucassen et al., 2010) and phosphor-
histone-3 (Gomez-Nicola et al., 2014) but there exists a need for consistency 
between studies in the markers used to label proliferation.  
 
More recently, radiocarbon dating of human brain tissue has been used to detect 
proliferation. This technique utilises increases in atmospheric levels of the isotope 
14C due to nuclear bomb testing in the 1960s. The spike in atmospheric levels of 14C 
was followed by a predictable exponential decrease and thus cells can be dated 
relative to atmospheric 14C (Spalding et al., 2008, Spalding et al., 2005a, Spalding et 
al., 2005b). The nuclei of neuronal and non-neuronal cells from postmortem 
samples can then be sorted by flow cytometry and 14C levels assayed to determine 
their mean age relative to the age of the donor (Bergmann et al., 2012, Bhardwaj et 
al., 2006, Ernst et al., 2014, Spalding et al., 2013, Spalding et al., 2005a). This 
technique is restricted to very few laboratories worldwide and requires complex 
mathematics to gather meaningful data (Bernard et al., 2010) so its application for 
adult neurogenesis studies is limited. 
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1.2.4.2 Migration 
Once a neuroblast has proliferated it begins migrating to where it may become 
integrated as a functional neuron; to the OB via the RMS for the SVZ or to the 
adjacent GCL from the SGZ. During this migratory phase, neuroblasts adopt a 
migratory phenotype with elongation of the nucleus which is thought to be due to 
cytoskeletal rearrangement to provide propulsion for the cell (Curtis et al., 2007b, 
Eriksson et al., 1998, Knoth et al., 2010, Zhang et al., 2009). The marker most 
commonly used to label migrating neuroblasts is polysialated-neural cell adhesion 
molecule (PSA-NCAM) (Bedard et al., 2002, Bonfanti, 2006, Bonfanti and Peretto, 
2007) although this shows almost complete overlap with DCX (Aelvoet et al., 2015, 
Knoth et al., 2010).  
 
1.2.4.3 Neuronal markers 
At various points along its journey a neuroblast will express particular proteins 
reflecting differing stages of maturation and subsequently downregulate these 
proteins. The combinations of these different markers allow the 
immunohistochemist to get a “snapshot” of a cell at a particular point of 
maturation. The most commonly used markers for the earliest stages of neuronal 
differentiation are neural stem markers such as vimentin (Seri et al., 2004, 
Weissman et al., 2003), nestin (Hendrickson et al., 2011), glial fibrillary acidic 
protein (GFAP)- (Sanai et al., 2011, Seri et al., 2004) and epidermal growth factor 
receptor (EGFR) (Aguirre et al., 2010, Gleeson et al., 1998, Sanai et al., 2011). As the 
neuroblasts continue to mature they upregulate DCX, a microtubule-associated 
protein (Gleeson et al., 1998, Knoth et al., 2010, Sanai et al., 2011) then eventually 
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express mature neuronal markers such as NeuN (Eriksson et al., 1998, Ernst et al., 
2014, Spalding et al., 2013). These markers are useful for correlating proteins 
associated with cells at different stages of maturation, however their functions 
within the cell remain largely unknown (reviews in (von Bohlen und Halbach, 2011, 
Ming and Song, 2011)). 
 
1.2.5 Adult neurogenesis in humans 
Whether neurogenesis continues into adulthood in humans remains a controversial 
issue. The first evidence to suggest adult neurogenesis did occur in humans was 
when Eriksson and colleagues studied the postmortem brains of cancer patients 
who had received injections of BrdU for diagnostic purposes. Double-labelling 
studies with BrdU using mature cell specific markers, such as NeuN, can confidently 
predict the fate of a cell that has undergone mitosis. Using this technique, Eriksson 
was able to show BrdU-positive cells throughout the GCL, SGZ and hilus of the 
human hippocampus as well as a subset that co-localised with NeuN, (Eriksson et 
al., 1998). Whilst interesting, the tissue used in this study was by its nature 
pathological and should be interpreted with caution. Knoth and colleagues 
demonstrated DCX-positive cells within the DG however they reported varying co-
localisation with proliferative markers (Knoth et al., 2010). Perhaps the most 
convincing evidence for adult human hippocampal neurogenesis thus far is the use 
of radiocarbon dating techniques. Spalding and colleagues used radiocarbon dating 
techniques have suggested that there are upwards of 1400 new neurons born per 
day in the adult hippocampus (Spalding et al., 2013). Yet even with evidence of 
markers of adult neurogenesis in the adult human hippocampus there is known to 
 13 
be a precipitous drop off in early childhood (Knoth et al., 2010) and the functional 
relevance of this process beyond adolescence is questionable.  
 
The literature describing the other neurogenic niche, the SVZ, is similarly 
controversial. The first suggestion of the existence of adult neurogenesis in the 
human SVZ came from Curtis and colleagues who used PCNA to demonstrate co-
localisation with the immature neuronal marker beta-tubulin III (Curtis et al. 2003). 
The authors then went on to show that PCNA-positive cells extended from the walls 
of the lateral ventricle to the olfactory tract as a functional RMS (Curtis et al., 
2007b). A major concern in this study however was the use of PCNA as a 
proliferative marker. The finding of a tract of PCNA-positive cells is undoubtedly an 
interesting discovery but Curtis and colleague’s conclusion that this is suggestive of 
the existence of an RMS in humans has been questioned by other authors (Sanai et 
al., 2007). Further studies have found DCX-positive neuroblasts (Wang et al., 2011) 
and GFAP-δ (van den Berge et al., 2010) within the adult SVZ, albeit rarely co-
localising with proliferative markers and given DCX has also been reported to label 
some mature astrocytes (Verwer et al., 2007) these results as evidence of ongoing 
SVZ neurogenesis must be interpreted with caution. 
 
If there were a functional RMS in humans, then new born neurons should be 
observed in the OB. Indeed, an early study showed the presence of both PCNA- and 
Ki67-positive cells in the OB as well as nestin and DCX (Bedard and Parent, 2004). 
However, unlike in the SGZ, radiocarbon dating has not supported a functional RMS 
in humans with one study showing that cell turnover in the OB is due to non-
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neuronal cells (Bergmann et al., 2012), or alternatively that adult-born neurons 
from the SVZ travel to the adjacent striatum rather than the OB via the RMS (Ernst 
et al., 2014). In support of Bergmann et al.’s findings another study showed that 
identifiable proliferative cells in the adult human OB were microglia (Sutherland et 
al., 2013). Lastly an exhaustive study of sixty brains aged one day to 84 years using 
the alternative proliferative marker, Ki67 and immature neuronal marker, DCX, 
demonstrated that the RMS is robust in very early childhood, but this process is 
almost completely extinct beyond 18 months of age (Sanai et al., 2011). 
 
From the review of the literature it is clear that there remains contention amongst 
the scientific community as to the extent of neurogenesis in the adult human brain. 
Notably, there is no consensus or “Gold Standard” around the most appropriate 
methodology for investigating adult neurogenesis. Studies thus far have been 
limited by their use of unreliable markers such as PCNA and no previous work has 
examined both neurogenic niches simultaneously in the same individuals. This 
heterogeneity across studies has made it difficult to understand what a “normal” 
level of neurogenesis is and clarity is needed in the area. 
 
1.3 Cell proliferation in alcohol-related brain damage 
 
Studies of adult neurogenesis in human pathological states are currently limited 
due to the controversy surrounding the very existence of adult neurogenesis in 
humans. Nevertheless, some efforts have been made in disease states such as 
epilepsy (Gonzalez-Martinez et al., 2007), Huntington’s Disease (Curtis et al., 2003) 
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and ARBD (Sutherland et al., 2013). Sutherland and colleagues used postmortem 
human brain tissue from chronic alcoholics and age- and gender-matched controls 
to examine cell proliferation in the SVZ (Sutherland et al., 2013). The major finding 
of this study was that there was no difference in PCNA-positive cells between the 
two groups. In addition to this there was also one chronic alcoholic case that had 
PCNA-positive cells throughout the caudate nucleus underlying the SVZ which was 
excluded from the study. On further examination, it was noted that this case also 
had a pathological diagnosis of HE. 
 
1.4 Hepatic Encephalopathy 
 
HE is a neuropsychiatric disorder that encompasses a wide range of clinical signs 
and symptoms from mild cognitive dysfunction and personality changes through to 
coma and death. The pathogenesis of HE is complex and currently poorly 
understood which limits management options for this debilitating condition. 
 
1.4.1 The burden of Hepatic Encephalopathy 
HE is a significant cause of morbidity and mortality in the community and a poor 
prognostic marker for patients with liver disease (Bustamante et al., 1999) as well 
as becoming an increasing economic burden on the health system (Poordad, 2007). 
Due to the careful psychometric testing required for the diagnosis of HE combined 
with clinical signs that can sometimes be subtle and no definitive diagnostic test it is 
difficult to ascertain its prevalence. A large, multi-centre study in the USA estimated 
that HE accounted for 0.33% of all hospitalisations between 2005-2009 however 
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the authors acknowledge that HE is often co-morbid with other conditions and not 
accounted for if it is not the primary diagnosis at admission (Stepanova et al., 
2012). HE can arise from any form of liver failure but is most likely when cirrhosis is 
present with hospital-based studies estimating that between 6-16% of cirrhotic 
patients have clinically evident HE (D'Amico et al., 1986, Saunders et al., 1981). HE 
is also an ongoing issue beyond acute presentations in patients with liver disease, 
with a community-based study finding that 11% of individuals had HE in the five 
years after their initial diagnosis of alcoholic cirrhosis (Jepsen et al., 2010). 
Determining the prevalence of HE is further complicated by lesser forms of the 
disease known as “subclinical” or “minimal” HE (mHE) which can go unnoticed but 
have a significant impact on a patient’s quality of life, even affecting an individual’s 
ability to drive (Bajaj et al., 2007, Bajaj et al., 2008). Estimates of mHE in cirrhotic 
patients range from 27%-80% (Das et al., 2001, Groeneweg et al., 2000, Romero-
Gomez et al., 2001, Saxena et al., 2001, Ortiz et al., 2005). 
 
1.4.2 Diagnosis and classification of Hepatic Encephalopathy 
 
HE has been defined as “a spectrum of neuropsychiatric abnormalities seen in 
patients with liver dysfunction after exclusion of other brain diseases” (Ferenci et 
al., 2002). This spectrum of abnormalities can make classification of HE difficult 
however the current gold standard is the West-Haven criteria whereby a patient is 
given a score from one to four based on their clinical picture (Conn et al., 1977). An 
individual with stage one HE will present with a trivial lack of awareness, impaired 
attention, sleep disturbances and mild confusion with increasing neurological 
deficits through to stage four patients who are comatose (Montagnese et al., 2014). 
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A further, subtler classification was added later for patients with no discernible 
changes in personality or behaviour but upon psychometric testing show impaired 
memory, concentration and executive function which is termed, the so-called mHE 
(Amodio et al., 2004, Ferenci et al., 2002).  
 
Given that HE has wide ranging aetiologies and is essentially a diagnosis of 
exclusion further classification is required beyond the West-Haven Criteria to guide 
management and treatment. This includes classification by the underlying disease 
as A (acute liver failure (ALF)), B (portosystemic shunting) or C (cirrhosis); by the 
time-course as episodic, recurrent or persistent and whether an episode is 
precipitated or non-precipitated (Table 1.1) (Vilstrup et al., 2014). For example, a 
HE patient could be described as type C, grade 3, persistent, non-precipitated HE. 
 
Table 1.1 - Grading of Hepatic Encephalopathy 
 
Taken from Vilstrup et al. 2014. 
 
1.4.3 Non-alcoholic causes of liver damage in Hepatic Encephalopathy 
 
Alcohol is a common causative factor for liver damage and consequently HE, but HE 
can arise from liver dysfunction of any aetiology. Although good epidemiological 
data on the prevalence of liver disease in Australia are currently lacking, and 
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particularly variable depending on methods of detection and diagnosis used, non-
alcoholic fatty liver disease (NAFLD) is now identified as the most prevalent liver 
disease in Australia (The Gastrological Society of Australia/Australian Liver 
Association, 2013). Estimates in the USA are approximately 20% of the general 
population (Browning et al., 2004, Clark, 2006, Weston et al., 2005) with increasing 
incidence in the Asia-Pacific regions (Fan et al., 2005, Chitturi et al., 2007). 
 
NAFLD can be divided into two conditions: non-alcoholic steatohepatitis (NASH) 
and simple steatosis (non-NASH). Importantly, NASH can progress to fibrosis and 
cirrhosis whilst simple steatosis is relatively benign. The primary risk factors for 
NASH is obesity and Type II diabetes mellitus with a “two-hit” hypothesis of lipid 
dysregulation and oxidative stress leading to hepatocyte damage (Jou et al., 2008). 
 
Notably, the pathological progression of NASH and alcoholic liver disease are similar 
with the main distinction being a clinical exclusion of excessive alcohol 
consumption defined as more than 10g of ethanol per day for women and 20g 
ethanol per day for men (Digestive Health Foundation, 2007). Pathological features 
of both NASH and alcoholic liver disease on biopsy are early hepatocyte ballooning, 
the appearance of Mallory bodies (inclusions of damaged intermediate filaments in 
hepatocytes), lobular inflammation and a unique distribution of fibrosis in acinar 
zone 3. This can then progress to cirrhosis of the liver with extensive fibrosis along 
portal tracts and the appearance of regenerative nodules. 
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As previously stated, HE can arise from liver dysfunction of any aetiology, however 
many of the causative agents that can contribute to liver disease are often co-
morbid. It is reasonable to consider therefore that multiple factors such as altered 
lipid dysregulation and alcohol may contribute to the progression of HE beyond 
their obvious role contributing to hepatic damage. 
1.4.4 The pathogenesis of Hepatic Encephalopathy 
 
1.4.4.1 Ammonia and the astrocyte in Hepatic Encephalopathy  
An important function of the normal liver is metabolism of ammonia, a normal 
metabolite of amino acid catabolism and synthesis throughout the body. Under 
normal conditions, ammonia is converted to urea by glutamine synthetase in the 
liver however in pathological situations such as that of alcohol-induced liver 
cirrhosis (or liver failure of any aetiology) a lack of functional hepatocytes leads to 
increased levels of systemic ammonia (hyperammonaemia) (Qvartskhava et al., 
2015). As ammonia freely crosses the blood brain barrier (BBB), hyperammonaemia 
leads to elevated cerebral ammonia.  
 
In the brain ammonia is converted to glutamine via glutamine synthetase within 
astrocytes. Astrocytes exposed to high levels of ammonia in cell cultures 
(Norenberg et al., 1990) or animal models of hyperammonaemia (Norenberg et al., 
1997, Belanger et al., 2002) display a swollen phenotype, known as Alzheimer Type 
II Astrocytes (At2a), that were first described by Alois Alzheimer (Hosslin and 
Alzheimer, 1912). The development of At2a and consequently cerebral oedema is 
traditionally thought to be due to excessive glutamine acting as an osmolyte 
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drawing water into the cell. Emerging evidence however suggests that astrocyte 
swelling and dysfunction is mediated in part by ammonia and consequently 
glutamine overload inducing the mitochondrial permeability transition (Bai et al., 
2001). The mitochondrial permeability transition is “a sudden increase in the 
permeability of the inner mitochondrial membrane resulting from an overload of 
Ca2+” that leads to a collapse of the inner mitochondrial membrane potential. This 
consequently contributes to generation of reactive oxygen species (ROS), 
mitochondrial dysfunction, energy failure and ionic pump dysfunction (Rama Rao et 
al., 2003). 
 
At2a are considered the hallmark neuropathological feature of HE and 
consequently why HE is considered a primary gliopathy, with any neuronal 
dysfunction thought to arise secondary to astrocytic dysfunction. Microscopically 
At2a have swollen, pale nuclei with marginated chromatin (Martin et al., 1987) and 
decreased expression of the astrocytic marker GFAP (Kimura and Budka, 1986, 
Sobel et al., 1981, Kretzschmar et al., 1985). At2a are used for neuropathological 
diagnosis of HE based on the number of At2a present in frontal cortex, caudate 
nucleus and putamen, with individuals being semi-quantitatively scored as none, 
mild, moderate or severe (Kril and Butterworth, 1997) (Figure 1.1). 
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Figure 1.1 - Alzheimer Type II Astrocyte.  
Photomicrographs of Haematoxylin and Eosin stained sections show (A) normal 
astrocyte nucleus with diffuse chromatin and (B) swollen Alzheimer type 2 
astrocyte nucleus with marginated chromatin. Scale Bar = 10µm. Images provided 
courtesy of Professor Jillian Kril. 
 
1.4.4.2 Neurodegeneration in Hepatic Encephalopathy 
Given the finely tuned microenvironment of the brain it is also interesting to 
consider the neurotoxic potential of ammonia. As discussed above HE is generally 
considered to be a primary gliopathy, yet neuronal cell cultures treated with 
ammonia display cellular loss, decreased nuclear size and necrotic cells, while co-
cultures of neurons and astrocytes treated with ammonia show no change 
compared to vehicle treated cells (Rao et al., 2005). This is presumably due to the 
ammonia detoxification and anti-oxidant potential of astrocytes however this study 
only examined short-term ammonia treatment before “Alzheimer Type II 
astrocytosis” had occurred. There is the possibility that a more chronic exposure to 
ammonia and subsequent astrocytic dysfunction could diminish the protective 
capacity of the astrocytes leading to neurodegeneration. 
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1.4.4.3 Inflammation and Hepatic Encephalopathy 
Elevated levels of ammonia in the blood have always been acknowledged as a 
prominent feature of HE (Traeger et al., 1954), however it is now recognised that 
there are other factors likely at play that act synergistically with ammonia to drive 
the pathogenesis of HE such as systemic inflammation (Shawcross et al., 2010). 
Arterial ammonia is used as a predictor of both the development of HE as well as 
intracranial haemorrhage in ALF (Bernal et al., 2007), however there lacks a 
consistent quantitative relationship in patients with chronic liver disease and 
cirrhosis. Undoubtedly, generalised elevation of ammonia occurs in HE but there is 
no consistent prognostic or predictive value in arterial ammonia in cirrhotic 
patients (Phear et al., 1955, Shawcross et al., 2011). Ong and colleagues showed 
elevated ammonia levels in grade three and four HE only but also reported 
elevations in cirrhotic patients with no neurological impairments (Ong et al., 2003). 
 
Given the disparity between arterial ammonia and HE grading, it seems other 
factors could be contributing to the development of HE. There is evolving evidence 
now proposing a role for systemic inflammation as a modulating factor of HE 
(Shawcross and Jalan, 2005, Shawcross et al., 2010). Patients with liver cirrhosis are 
functionally immunosuppressed predisposing them to the development of 
infections (Wasmuth et al., 2005). This can consequently lead to a Systemic 
Inflammatory Response Syndrome (SIRS) with elevations of inflammatory markers 
such as C-reactive protein, leukocytes, cytokines as well as a febrile state. Rather 
than ammonia it is inflammatory markers (temperature, white blood cell count, 
heart rate, respiratory rate) that are higher in grade four HE (Shawcross et al., 
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2011). Consistent with this hypothesis, markers of systemic inflammation have 
been shown to be predictive of a patient’s progression from stage 1/2 HE to 3/4 in 
ALF (Vaquero et al., 2003) 
 
Further evidence for hyperammonemia alone not being sufficient to cause HE was 
provided in a hospital study of patients with SIRS. Patients admitted to hospital 
with SIRS and no overt signs of HE who were given a simulated gastrointestinal 
bleed to induce hyperammonemia showed impairment on neuropsychological 
testing. However, if the same procedure is repeated after the resolution of SIRS no 
neuropsychological deficit is seen (Shawcross et al., 2004).  
 
A role for SIRS in HE not only presents a potential therapeutic avenue but also 
offers different insights into the pathogenesis of the disease. In liver failure gut 
derived bacteria can evade the mononuclear phagocyte system due portal-systemic 
shunting (Cirera et al., 2001) and there are also changes in the permeability of the 
intestinal wall (Pascual et al., 2003) allowing bacteria to translocate to extra-
intestinal sites which is exacerbated by chronic alcoholism (Keshavarzian et al., 
1999). Beyond this, liver failure and cirrhosis reduce hepatic production of innate 
immune components such as complement and cause inherent dysfunction of the 
cells of the innate immune system. Human leukocyte antigen (HLA)-DR, a molecule 
found on monocytes is involved in antigen-presentation and an important 
component of the innate immune system. Patients with acute-on-chronic liver 
failure show a decreased monocyte expression of HLA-DR (Wasmuth et al., 2005), 
which may contribute to their propensity to develop infections and sepsis. 
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Furthermore, patients with decompensated cirrhosis and decreased HLA-DR 
expression have a higher mortality, predominantly due to sepsis and levels of HLA-
DR below 40% is a predictor of poorer outcome in these patients (Berres et al., 
2009, Berry et al., 2011).  
 
Shawcross et al. have proposed that neutrophil dysfunction also contributes to HE 
pathogenesis via an interaction with ammonia (Shawcross et al., 2010). Neutrophils 
take up invading microbes and destroy them by the generation of a reactive 
oxidative burst. Although this is an effective method of eliminating foreign matter, 
the generation of free radicals can damage surrounding tissue and generate an 
inflammatory response. In both rats fed a high ammonia diet as well as cirrhotic 
patients who are given an amino acid meal to stimulate hyperammonaemia 
neutrophils have a diminished phagocytic function, increased spontaneous 
oxidative bursts and cell swelling which is proposed to occur via the p38-MAPK 
osmoregulatory pathway (Coltart et al., 2013, Shawcross et al., 2008). This 
neutrophil dysfunction therefore not only compromises immune function but may 
also contribute to the inflammation creating a vicious cycle. 
 
Whilst there is a clear inflammatory component and increased circulating cytokines 
in liver failure (Jover et al., 2006), whether this increase in circulating inflammatory 
factors can influence brain function and contribute to the encephalopathy depends 
on whether they can enter the brain. Under normal conditions, cytokines are too 
large (15-20kDa) and cannot cross the BBB. In animal models of HE, the BBB 
remains intact until the terminal stages of the disease (Rangroo Thrane et al., 2012, 
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McMillin et al., 2015) and is often only compromised when sepsis occurs or it is 
induced with injected lipopolysaccharide (Chastre et al., 2014), although other 
studies using a similar experimental design fail to demonstrate this (Wright et al., 
2007a). Human studies of the BBB in HE are limited but early evidence using 
electron microscopy showed endothelial cell and astrocytic foot processes swelling 
but the tight junctions remaining intact in HE (Kato et al., 1992). Although not 
directly in the setting of HE early studies suggested an increase in BBB permeability 
in response to ammonia in severe liver disease (Lockwood et al., 1991), but more 
recent MRI studies could not confirm this finding (Goldbecker et al., 2010). Yet, 
there may be alterations in permeability caused by tumour necrosis factor (TNF)-
alpha upregulating endothelial cell expression of matrix metalloproteinase-9 and 
downregulating claudin-5, a membrane protein associated with endothelial tight 
junctions (McMillin et al., 2015).  
 
Clearly there is an inflammatory role in the development of HE, which is affecting 
both the adaptive and innate peripheral immune system. It is therefore interesting 
to consider a potential role for the primary immune cells of the CNS, the microglia. 
 
1.5 Microglia 
 
There are four major cell types that comprise the CNS: neurons, the main functional 
unit, astrocytes, the principal supporting cell, oligodendrocytes, the myelin 
producing cells and microglia. The existence of a mesodermal-derived component 
in the brain was first proposed in the early 20th Century and was termed “The Third 
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Element” (Cajal, 1913b, Cajal, 1913a, Cajal, 1920, Robertson, 1900a, Robertson, 
1900b). Initially proposed by Ramon y Cajal, the existence of these cells was then 
demonstrated by one of his students, Pio del Rio Hortega in 1932, using a silver 
carbonate staining technique who consequently coined the term microglial cells 
(Del Rio-Hortega, 1932). Despite this initial discovery, microglia were not widely 
accepted as a distinct cell type in the CNS until relatively recently (20 years), since 
then there has been increasing interest in microglial involvement in health and 
disease. 
 
1.5.1 Origins 
Microglia originate as yolk sac-derived monocytic cells that migrate to the brain 
during early embryonic development where they mature, take on a ramified 
phenotype and remain throughout life (Kettenmann et al., 2011). In addition, a few 
circulating monocytes throughout adult life are thought to cross the intact BBB to 
replace the resident population of microglia (Ajami et al., 2007, Asheuer et al., 
2004). Microglia are estimated to make up 5-15% of the cell population in the adult 
human brain however it is a very heterogeneous population varying in both number 
and morphology throughout the brain (Mittelbronn et al., 2001, Lawson et al., 
1990). 
 
1.5.2 The role of microglia in the normal CNS 
Traditionally, microglia have been viewed as resting bystander cells, similar to those 
cells of the innate immune response in the periphery, whose only roles are to 
become activated in response to foreign material and take on a predominantly 
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phagocytic role to eradicate the invading threat to the CNS. Undoubtedly, an 
important role of microglia is to respond to these challenges, when within minutes, 
they proliferate and migrate to sites of injury and have stereotypic responses 
involving morphological changes and cytokine production depending on the 
triggering stimulus. Yet physiological functions of microglia beyond their phagocytic 
role are rapidly being uncovered and the paradigm of microglia as merely a 
quiescent population ready to respond to an insult is now defunct. Microglia are 
now known to constantly survey their microenvironment (Nimmerjahn et al., 2005) 
and have roles in synaptic stripping (Trapp et al., 2007, Wake et al., 2009), removal 
of apoptotic cell material (Magnus et al., 2001) as well as proposed roles in 
neuronal signalling via microglial derived adenosine triphosphate (ATP) signalling 
astrocytes to release glutamate (Tremblay et al., 2011).  
 
The brain is normally an immune privileged site due to the presence of the BBB 
preventing entry of the majority of substances and most circulating immune cells 
into the brain. It is therefore the microglia that are responsible for local immune 
surveillance of the CNS. Under normal conditions, microglia have a small, rod-
shaped nucleus with many fine, highly branched processes extending into the 
surrounding parenchyma. Until recently, this ramified morphology was considered 
to represent a “resting” state with little physiological significance. A pioneering 
study overturned this previous dogma demonstrating that microglia are in 
persistent motion. Using two-photon live imaging, the authors were able to 
demonstrate microglial cells in mice are constantly forming and withdrawing their 
processes to monitor their surroundings for foreign or injured/necrotic material 
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(Nimmerjahn et al., 2005). This constant motility also involved the processes 
contacting all cell types, implicating a role for microglia regulating and being 
regulated by both neurons and astrocytes (Nimmerjahn et al., 2005). Indeed, the 
very notion of the brain as an immune privileged site has also been challenged by 
the discovery of a ‘lymphatic’ or glymphatic system in mouse brain and preliminary 
evidence for a similar system in humans (Louveau et al., 2015) as well as areas 
known to lack a BBB such as the circumventricular organs. 
 
Synaptic stripping by microglia was first posited fifty years ago in regenerating 
motor neurons of the mouse brainstem (Blinzinger and Kreutzberg, 1968) and more 
recently in the cerebral cortex (Trapp et al., 2007). Microglia transiently contact 
both pre-and post-synaptic terminals under normal conditions and interestingly 
remain in contact for longer with more active neurons (Wake et al., 2009) and it is 
postulated that these can then remove exuberant or dysfunctional synapses. The 
most striking evidence for the importance of microglial synaptic stripping in the 
maintenance of normal adult CNS functioning comes from a mutant mouse line 
bred to eliminate microglia only in adults (Parkhurst et al., 2013). Previous attempts 
at microglial depletion could not rule out synaptic aberrations due to impaired 
synaptic pruning during development (Koeglsperger et al., 2013, Rogers et al., 
2011). These microglia-depleted adult animals have impaired learning ability as well 
as reduced dendritic spine elimination and formation. 
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1.5.3 Microglial activation 
Of interest, particularly with regard to pathological situations, is the concept of 
microglial activation. This process involves stimulation of microglia by exogenous or 
endogenous material or signals leading to morphological changes and alterations in 
expression of “activation” proteins to respond to the stimulus. Traditionally 
microglial activation was widely viewed as a damaging process and has become 
synonymous with the term “neuroinflammation”. An important distinction however 
needs to be made between these two terms as highlighted by Graeber and 
colleagues (Graeber et al., 2011). Here, the authors identify three main problems 
with the term neuroinflammation: (i) microglial activation does not display the 
stereotypical definitions of inflammation such as infiltration of circulating immune 
cells, (ii) opening of the BBB is not required for microglial activation, and (iii) 
although a pathological diagnosis of Creutzfeld-Jacob disease requires an absence 
of inflammatory cells, microglial markers are upregulated in this disease. Essentially 
the distinction here is that neuroinflammation implies a damaging, uncontrolled 
inflammatory process involving various components of the immune system 
whereas microglial activation is a finely tuned process that may occur under normal 
as well as pathological conditions. Accordingly, whilst microglia can create a pro-
inflammatory environment and potentially neurotoxic environment when 
activated, Graeber has proposed that microglial activation may in fact be a 
protective effort to “help” neurons under stress (Graeber, 2010). 
 
The microglial activation response is a finely tuned and specialised response. 
Activation is no longer recognised as a simple “on or off” process limited to classical 
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(M1) and alternative (M2) activation states (Michelucci et al., 2009) but more likely 
occurs as a spectrum with constant minor shifts in activation occurring 
(Kettenmann et al., 2011). Detecting activated microglia in postmortem tissue 
remains a challenge as there is currently no universal marker of activation. There 
are however a number of recognised features of microglial activation that can be 
exploited to identify microglial activation. The most obvious change is a 
morphological shift, with ramified cells withdrawing their process, increasing 
number and adopting a “bushy” appearance. Objective cluster analysis of mouse 
microglia has identified three morphological sub-types of microglia (Yamada and 
Jinno, 2013) similar to the range of morphologies seen in human brain tissue (Streit 
et al., 2014). Morphological changes are a useful tool for the detection of activation 
but the function of an activated cell cannot be extrapolated from morphology 
alone. The function of an activated microglial cell varies depending on the 
activating stimulus and can even be region dependant (Choi et al., 2012). 
Accordingly, a combination of morphological and immunohistochemical markers 
are required for an accurate interpretation of microglial function. 
 
Unlike most cells in the CNS, microglia retain the ability to proliferate throughout 
life. This can occur as part of the activation response to increase microglial 
numbers, particularly in acute insults such as stroke, demyelination and facial nerve 
axotomy (Graeber et al., 1988, Lalancette-Hebert et al., 2007, Remington et al., 
2007). Microglial proliferation is not entirely synonymous with activation, and most 
commonly activation occurs in the absence of proliferation (Serrano-Pozo et al., 
2013) with specific signalling required such as through colony-stimulating factor 1 
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receptor is required (Rakic and Zecevic, 2000). Nevertheless, it is important to 
detect when microglial proliferation is present and proliferative markers such as 
Ki67 and PCNA can be used (Gomez-Nicola and Boche, 2015, Olmos-Alonso et al., 
2016, Sutherland et al., 2013).  
 
Other markers that are used for microglial activation include cluster of 
differentiation (CD)68, a lysosomal protein thought to have a role in phagocytic 
activity (Doorn et al., 2014, Martinez et al., 2013, Zotova et al., 2013, Bauer et al., 
1994), HLA-DP, Q and R (or major histocompatibility complex-II in rodents) is a cell 
surface protein associated with T-helper cell activation (O'Keefe et al., 2002, Raivich 
et al., 1999). Under normal conditions with an uncompromised BBB, T-cells are 
rarely present in the brain however HLA antigens can be detected on some ramified 
microglia in normal human brain (Gehrmann et al., 1993, Hayes et al., 1987). It is 
therefore unclear what the function of HLA proteins are in microglia and their role 
in activation. CD11b is an integrin alpha chain and combined with CD18 makes up 
complement receptor 3 (CR3). CD11b is again also expressed constitutively on 
microglia but has been proposed to be a marker of “early” activation (Hynes, 1992, 
Marshall et al., 2016, Robinson et al., 1986). More recently the complement system 
has been identified as a pathway for synaptic removal. Complement has been 
shown to be expressed in synaptic terminals in mouse retina leading to detection 
and removal by microglia through the CR3 (Chu et al., 2010, Stevens et al., 2007). 
Clearly microglial activation is a complex, multi-faceted process, the functional 
implications of which are still incompletely understood. 
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The fate of a microglial cell after it is activated is not well understood but an 
important consideration in chronic conditions. In many pathological states such as 
stroke (Ito et al., 2001) and binge alcohol abuse (Marshall et al., 2013), microglia 
will become activated but over time the majority of microglia have a ramified 
morphology in the affected area. Whether these are the same cells returning to a 
ramified morphology or replaced over time by local proliferation is unknown. 
Nevertheless, whether a microglial cell that has been activated previously can 
retain the normal homeostatic functions of a ramified microglial cell that has never 
been activated is up for debate. This leads to the concept of microglial priming, 
(Perry, 2010, Raj et al., 2014, Sheng et al., 1997) whereby previously activated 
microglia are hyper-responsive to future insults later in life. This has been 
demonstrated in a model of repeated ethanol binges where animals that receive 
multiple binge episode have higher numbers of microglial activation markers 
compared to a single binge (Marshall et al., 2016). This priming has also been 
suggested to play a role in early-life seizures (Somera-Molina et al., 2009). 
 
Microglial activation is now widely considered to be a tightly regulated, and for the 
most part, a protective response. Problems arise however when activation 
becomes chronic and it is postulated that damage to the CNS occurs once microglia 
and their protective properties are lost. This was first proposed in a seminal paper 
by Streit and colleagues who demonstrated that microglial activation occurs in the 
brains of Alzheimer’s disease patients without neuronal loss or A pathology (Streit 
et al., 2009). Notably, it was shown that microglial degeneration preceded the 
spread of tau pathology. This degenerative phenotype was termed “dystrophic 
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microglia”, a phenotype also known as cytorrhexis, characterised by beading of the 
cytoplasmic processes whilst the nucleus remains intact. Streit and colleagues 
hypothesised that chronic activation of microglia leads to microglial dystrophy and 
without the protective functions of microglia, neurodegeneration occurs (Streit, 
2006, Streit et al., 2004, Streit and Xue, 2009, Streit et al., 2014). 
 
Microglia are clearly dynamic and versatile cells and a crucial component of the 
CNS. Given their protective as well as potentially damaging properties, they are an 
important consideration in any neurological disease. 
 
1.5.4 Microglia and HE 
Cytokines cannot diffuse freely across the BBB and in HE, while the BBB may remain 
intact, systemic cytokines can still influence the brain by alternative routes of entry. 
One such route is signal transmission via peripheral nerves and another is cytokines 
acting via secondary messengers on the brain’s endothelial lining (reviewed in 
(Licinio and Wong, 1997)). For example, cerebral vascular cells contain receptors to 
interleukin (IL)-1 which, when stimulated by IL-1 trigger the production of 
cyclooxygenase-2 (COX-2) and prostaglandin E2 that can then diffuse through the 
BBB into the brain parenchyma (Ek et al., 2001, Hashimoto et al., 1991). Once such 
inflammatory mediators are within the brain they can signal resident cells such as 
the microglia, astrocytes or even neurons to produce a range of cytokines. 
 
More recently, there has been evolving evidence for the involvement of microglia in 
the pathogenesis of HE, although whether this is in a beneficial or deleterious 
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capacity is an area of debate. Reports have demonstrated an upregulation of the 
microglial marker ionised calcium binding adaptor molecule-1 (Iba1) in the brains of 
individuals with cirrhosis and HE whilst cirrhotic individuals without HE had no 
change in Iba1 levels (Zemtsova et al., 2011). Furthermore, a genome wide 
microarray showed an upregulation in gene expression for markers associated with 
microglial activation such as CD14, CD163 and MHC-II transactivator (CIITA) as well 
as molecules associated with toll-like receptors (e.g. TLR-2) that are thought to be 
exclusively expressed on microglia (Gorg et al., 2013, Kielian et al., 2002).  
 
The extent of microglial involvement depends on the experimental paradigm used, 
which is particularly complicated by the lack of a definitive animal model of HE. Rats 
that have undergone end-to-side portacaval anastomosis display microglial 
activation at pre-coma and coma stages of encephalopathy (Jiang et al., 2009b, 
Jiang et al., 2009c) whereas intraperitoneal (i.p.) injection of the hepatotoxin, 
azoxymethane, only induced microglial activation at coma stages of 
encephalopathy in both mice (Rangroo Thrane et al., 2012) and rats (McMillin et al., 
2014). Conversely models of hyperammonemia exhibit regional microglial 
activation without coma although subtler neurological deficits such as impaired 
spatial learning (Hernandez-Rabaza et al., 2016) and motor activity (Rodrigo et al., 
2010) are seen. 
 
Whether this microglial activation is beneficial or deleterious in the setting of HE is 
currently unknown. Nevertheless, it is interesting to note that animal studies of HE 
where microglial activation is attenuated through inhibition of chemokine ligand 2 
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(CCL2) show slowed neurological decline (McMillin et al., 2014) and a similar effect 
is seen in hyperammonemic rats when treated with the NSAID, ibuprofen or anti-
oxidant, sulforaphane (Hernandez-Rabaza et al., 2016, Rodrigo et al., 2010). 
 
1.6 Animal models of HE 
 
HE is a complex disease with an unknown and very likely multifactorial 
pathogenesis and as such modelling the disease is difficult. An important 
consideration when considering animal models is the chronicity of the human 
disease. Currently there are reliable models of acute of Type A HE due to ALF but no 
useful model for chronic Type B and C HE (Butterworth et al., 2009) 
 
Butterworth et al. proposed several criteria that should be satisfied when 
developing a reliable model of type B and C HE: (i) Chronic liver disease with portal-
systemic shunting, (ii) range of symptoms of encephalopathy from mHE to coma, 
(iii) Alzheimer type II astrocytosis at coma stages of encephalopathy, (iv) 
hyperammonaemia, increased brain ammonia/glutamine, (v) precipitating factor, 
(vi) clinical response to established treatments (Butterworth et al., 2009). Currently, 
the most commonly used method for creating animal models of HE is inducing liver 
damage by hepatotoxic agents. 
 
1.6.1 Hepatotoxins 
The use of hepatoxins such as azoxymethane (McMillin et al., 2014, Rangroo Thrane 
et al., 2012), thioacetamide (TAA) (Farjam et al., 2012, Ding et al., 2015, Faleiros et 
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al., 2014, Miranda et al., 2010) or carbon tetrachloride (Miquel et al., 2010) induce 
severe liver pathology and almost certainly reflect Type A HE (Butterworth et al., 
2009). Most efforts to induce HE using hepatotoxins use large bolus doses that 
usually lead to animals becoming comatose and dying or being sacrificed over a 
matter of days (Avraham et al., 2011, Farjam et al., 2012, Gomides et al., 2014).  
 
TAA is a well-established hepatotoxin that causes oxidative stress (Okuyama et al., 
2003, Witzmann et al., 1996), lipid peroxidation, glutathione depletion (Sanz et al., 
2002, Zaragoza et al., 2000) and impaired tissue repair (Chanda and Mehendale, 
1994, Stankova et al., 2010) leading to centrilobular necrosis (Okuyama et al., 
2003). Routes of delivery and dosages used vary from i.p. injections regulated for 
body weight (Avraham et al., 2011, Fernandez-Lizarbe et al., 2009, Honda et al., 
2002, Miranda et al., 2010, Rama Rao et al., 2010) or via drinking water (Mendez et 
al., 2008). Some efforts have been made to develop a more chronic model using 
TAA at a lower dose (200µg/g) which demonstrated extensive liver fibrosis but no 
behavioural testing was done on the animals to assess HE (Honda et al., 2002).  
 
Hepatotoxins are useful predominantly due to their simplicity and ease of use. HE is 
likely a multifactorial disease so relevant modelling may require a multifactorial 
design. The use of a large dose hepatotoxin alone fails to acknowledge potential 
synergistic effects of other, often concurrent, factors in HE and liver disease such as 
alcohol and fatty liver diseases. 
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1.6.2 Ethanol 
Alcohol can be delivered via intragastric lavage (Duly et al., 2015), liquid diets 
containing ethanol (Ren et al., 2016) or via access to an ethanol bottle in the home 
cage (Blizard et al., 2004). Intragastric lavage is useful due to the ability to deliver a 
known amount of ethanol, however it is an invasive procedure and used to model 
“binge” alcohol use. Importantly, the dose given needs to be considered in the 
context of human alcohol misuse. For example, Qin et al. delivered a binge of 
ethanol by intragastric lavage to C57BL/6 mice at a dose of 5g/kg each day. 
Extrapolating to a 70kg man, this dose is equivalent to ingesting 350g of ethanol (35 
standard drinks) in one bolus. This equates to one and a half bottles of full strength 
scotch whiskey (40% v/v) and undoubtedly is a massive dose of ethanol to receive 
and likely to overestimate patterns of human alcohol consumption. 
 
Ideally, alcohol would be consumed voluntarily by animals however this is 
complicated by differing “preferences” for alcohol with alcohol preferring animals 
such as C57BL/6 mice and others such as BALB/c being “non-alcohol preferring”. 
Certain strains of mouse will avoid pure alcohol but this can be overcome by 
techniques such as titrating up the alcohol dose (Blizard et al., 2004), offering a 
“two-bottle choice” (McClearn and Vandenbergh, 2000), or supplementing alcohol 
with a sweetener such as saccharin (Yoneyama et al., 2008). Additionally, daily dose 
can be increased by exploiting the “alcohol deprivation effect” (ADE) whereby rats 
will drink greater amounts of ethanol following a forced withdrawal period 
although such an effect is less clear in mice (Koros et al., 1999, Spanagel and Holter, 
1999, Tambour et al., 2008). 
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The “two-bottle choice” method is one of the simplest measures that can be 
employed to increase ethanol intake in certain strains of mouse. This technique 
gives animals the option of a bottle with water only and a second bottle containing 
an ethanol solution. This method has been widely shown to increase ethanol 
preference including in BALB/c mice and the effect is compounded by titrating the 
ethanol solutions up from a low percentage solution to the desired ethanol 
concentration (Blizard et al., 2004, Zhu et al., 2004). The benefit of the two-bottle 
choice is two-fold, not only does it increase raw ethanol intake but also avoids 
confounding effects of dehydration due to ethanol avoidance if only one bottle is 
available. Other simple methods such as regular monitoring and changing of 
solutions and switching the side of the cage each bottle is on to avoid a side 
preference are also important (Bachmanov et al., 2002). 
 
Perhaps one of the most effective methods for increasing voluntary ethanol intake 
is supplementing the ethanol solution with artificial sweeteners such as saccharin 
(Yoneyama et al., 2008). Non-alcohol preference in animals has been suggested to 
be due to the taste of ethanol (Belknap et al., 1993) and this can accordingly be 
masked by saccharin. 
 
As with all animal models each species and strain of animal has certain desirable as 
well as less desirable features depending on the model in question. Whilst non-
alcohol preference in certain strains can be problematic in studies of ethanol abuse 
it should not preclude entirely its use as a model, particularly in multi-factorial 
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experiments where other characteristics of a non-alcohol preferring animal may be 
advantageous. 
 
1.6.3 High-fat diets 
Another major contributor to liver disease and consequently HE is NAFLD. Not only 
does a high-fat diet (HFD) have direct pathological processes in the liver as 
described in section 1.4.3 but also has a synergistic effect with alcohol leading to 
increased inflammatory markers and fibrogenesis (Duly et al., 2015). Furthermore, 
there is evolving recognition of obesity and HFD having a direct impact on the brain 
with both mice fed HFD as well as humans with a body mass index (BMI) greater 
than 30 showing increased immunoreactivity of Iba1 and GFAP in the hypothalamus 
(Baufeld et al., 2016). Given this, it is useful to consider HFD in the context of HE. 
 
1.7 Conclusions 
 
HE is undoubtedly a multifactorial entity and the pathogenesis of the disease is 
currently poorly understood. Given alterations in neurogenesis in animal models of 
alcohol use (Hansson et al., 2010, Marshall et al., 2013, Nixon and Crews, 2004) 
although not in non-HE alcoholics (Sutherland et al., 2013) it is reasonable to ask if 
neurogenesis is affected in more severe, HE alcoholics. Yet, as illustrated above, the 
extent of adult neurogenesis is incompletely understood in humans and its 
prolificacy needs to be clarified in normal individuals before considering if, and how 
aberrations, might contribute mechanistically to diseases. 
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Lastly, whilst human studies are central to any research into a human disease 
process, those utilising postmortem human brain tissue are potentially confounded 
by many known and unknown variables present across an experimental cohort. 
Animal studies provide greater researcher control over potential confounders and 
are ideally utilised to test mechanistic hypotheses generated from human studies. 
At present, there exists no widely accepted animal model of chronic forms of HE for 
this purpose. 
 
1.8 Aims 
 
The overarching aim of this thesis is to improve the understanding of the 
pathogenesis of HE. This objective is divided into three specific aims:  
 
1. To quantify the level of adult neurogenesis in the SVZ and SGZ of 
postmortem human brain. 
 
2. To investigate cell proliferation in the neurogenic niches of chronic 
alcoholics with HE. 
 
3. To develop a model of chronic HE that has similar neuropathological 
changes to those seen in chronic alcoholics with HE. 
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1.9 Hypotheses 
 
1. Unlike the results of earlier studies that utilised the endogenous marker, 
PCNA, including one that looked at the neurogenesis in non-HE alcoholics, 
there are insufficient neurogenic events in the adult human brain to play a 
major role in neurological diseases. 
 
2. The majority of proliferating cells in the adult human brain are microglial 
and microglial turnover and behaviour is central to the pathogenesis of HE 
 
3. Microglial dysfunction is a prominent component of a murine model of 
chronic HE. 
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1.10 Structure of Thesis 
 
The following three chapters of results are presented as two papers which have 
been published in peer-reviewed academic journals and a final chapter presented in 
a “traditional” format.  
 
This laboratory has an interest in cell proliferation in the human brain and previous 
work has found no difference in cell proliferation in the SVZ of chronic alcoholics 
compared to age- and gender-matched controls using the endogenous marker 
PCNA (Sutherland et al., 2013). HE is a common complication of chronic alcohol use 
(Jepsen et al., 2010) and accordingly may feature alterations in cell proliferation in 
the neurogenic niches and elsewhere in the brain that are absent in 
“uncomplicated alcoholics”. During this initial study, however it was noted there 
was a lack of definition of the extent of cell proliferation in the normal human brain 
and significant technical questions, particularly in regards to the reliability of 
endogenous proliferation markers in human brain tissue. This thesis therefore 
aimed to understand cell proliferation in the normal brain and extrapolating from 
that any aberrations in cell proliferation that may be involved in HE. 
 
Chapter 2 incorporates a paper entitled “Human adult neurogenesis across the 
ages: An immunohistochemical study” that was published in the Journal of 
Neuropathology and Applied Neurobiology (Dennis et al., 2016). This work 
describes a rapid decline in cell proliferation and markers of neurogenesis in early 
childhood in both the SVZ and SGZ in neurologically normal individuals. This is an 
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important descriptive study of cell proliferation in the normal infant through to 
aged human brain which provides clarity to the area and allows future questions to 
be asked regarding the role of cell proliferation in disease. 
 
Chapter 3 presents a paper entitled “Microglial proliferation in the brain of chronic 
alcoholics with hepatic encephalopathy” in a special edition of Metabolic Brain 
Disease honouring Professor Roger Butterworth (Dennis et al., 2014). This work 
identifies that a subset of chronic alcoholics with HE have widespread microglial 
proliferation throughout their brains. Contrastingly, those without microglial 
proliferation displayed microglial dystrophy and associated neuronal loss in the 
superior frontal gyrus. Two questions remained at the conclusion of this work: i) if 
this widespread proliferation was a beneficial or deleterious process and ii) what 
was causing microglial proliferation in these cases. 
 
Chapter 4 is presented as a traditional results chapter and describes the 
development of an animal model of chronic HE and accompanying analysis of glial 
changes in these animals. 
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2 Human adult neurogenesis across 
the ages: An immunohistochemical 
study 
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To Whom It May Concern,  
Faculty of Medicine 
University of Sydney  
 
Re: “Human adult neurogenesis across the ages: An immunohistochemical study.” 
Paper accepted by the Journal of Neuropathology and Applied Neurobiology 
August 2016 to be included as part of Claude Dennis’ Thesis.  
 
This is a letter to state the following authors contributions to this paper which will 
be submitted as part of Claude Dennis’ Thesis:  
 
CD – Study design, data acquisition. Manuscript preparation  
LS – Data Acquisition.  
MR – Provision of juvenile tissue, proof reading and comments  
JK – Study design, proof-reading and comments.  
GS – Study design and manuscript preparation. 
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Fig. S1 – Counting frame for unbiased stereology of the SVZ and SGZ 
Micrographs of the SVZ and SGZ show the regions (red) where Ki67, DCX and PCNA 
were quantified. (A) The SVZ was defined as the area immediately beneath the 
ependymal layer of the lateral ventricle and the myelin layer that separates the SVZ 
from the underlying parenchyma. (B) The SGZ was defined as the area between the 
granule cell layer of the hippocampus and the boundary between the polymorphic 
layer and the CA4 subregion of the hippocampus which was determined by the 
presence of pyramidal neurons. 
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Fig. S2 - PCNA immunostaining in the human SVZ and SGZ 
PCNA immunostaining of the SVZ shows a similar staining pattern in four cases of 
different ages (A, C, E and G) with nuclear staining of variable intensity as well as 
staining of the post-mitotic ependymal layer. In the SGZ, PCNA immunostaining 
shows PCNA+ cells throughout all regions of the hippocampus in juveniles (B, D and 
F) and weak staining in a 54 year-old individual (H). 200x magnification. Scale bar = 
100μm. 
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Fig. S3 - Quantification of endogenous markers of proliferation and neurogenesis 
in the human SVZ. 
Scatter plots show the density of (A) Ki67+ and (B) DCX+ in the SVZ of 18 
neurologically normal donors aged 0.2-59 years. A solid line in (A) represents the 
mean density of Ki67+ cells in adult cortex and dotted lines indicate the standard 
deviation (2.90 ± 2.1 cells/mm2). (C) A histogram shows the density of 
immunopositive cells for Ki67, DCX and PCNA in each case.  
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Fig. S4 - Quantification of endogenous markers of proliferation and neurogenesis 
in the human SGZ 
Scatter plots show the density of (A) Ki67+ and (B) DCX+ cells in the SGZ of 18 
neurologically normal donors aged 0.2-59 years. A solid line in (A) represents the 
mean density of Ki67+ cells in adult cortex and dotted lines indicate the standard 
deviation. (C) A histogram shows the density of immunopositive cells for Ki67, DCX 
and PCNA in each case.  
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Fig. S5 Endogenous markers of proliferation in the RMS. Photomicrographs show 
traces of the RMS extending rostrally between the corpus callosum (CC) and 
caudate nucleus (CN). Higher magnifications of regions corresponding to black 
rectangles are shown in insets. Collages of overlapping fields show PCNA+ cells 
within the RMS of (A) a 0.2 year-old. The upper inset shows occasional intensely 
stained cells among many moderately stained PCNA+ cells. The lower inset shows a 
non-patent ependymal islet with an invagination of putative proliferative (SVZ-like) 
tissue. Intensely stained cells are present within the islet, the ependyma and 
adjacent tissue. (B) a one year-old with a single intensely stained cell adjacent to a 
moderately stained ependymal island and (C) a 54 year-old with moderately stained 
PCNA+ cells throughout the RMS. The inset shows the typical moderately intense 
immunostaining of the ependymal islets and adjacent SVZ-like tissue. Collages of 
overlapping fields show Ki67 immunostaining in the human RMS of (D) a 0.2-year-
old with upper inset showing Ki67+ cells clustered towards the CN and the lower 
inset showing an ependymal islet with Ki67+ cells within the islet as well as the 
adjacent SVZ-like tissue. (E) one year-old with rare Ki67+ cells (black arrows) in the 
RMS adjacent to the CN and (F) a 54 year-old with a single Ki67+ cell (black arrow).  
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2.1 Commentary on “Human adult neurogenesis across the ages: 
An immunohistochemical study 
 
Since its publication this article has received significant attention in the scientific 
press being one of the most accessed articles in the Journal of Neuropathology and 
Applied Neurobiology for 2016 (Appendix 2). The conclusions drawn in this article 
have been questioned by another author however, with Marucci providing a 
commentary (Appendix 3) (Marucci, 2016). Marucci raised a number of queries 
relating to this article. Firstly, he suggested that not investigating the transcription 
factor Sox2 was a significant oversight and would lead to underestimates of 
neurogenesis. Second, Marucci questioned the Ki67 cell counts presented here with 
reference to another paper that performed Ki67 counts in human tissue 
(Weissleder et al., 2016). Third, Marucci expressed reservations towards using 
postmortem human brain tissue in studies of neurogenesis and finally contrasts the 
findings presented here to studies using radiocarbon dating of human brain tissue 
(Spalding et al., 2013). 
 
Given the controversy surrounding neurogenesis and the sometimes 
overenthusiasm in the area given the potential therapeutic avenues a formal reply 
was warranted (full letter in Appendix 4). In the letter, it was acknowledged that 
Sox2 is a somewhat useful marker in neurogenesis studies however as it is mostly 
expressed in non-proliferating neural stem cells (Suh et al., 2007) it was unlikely to 
have been any more informative than the other markers used in this study. 
Marucci’s queries over differing Ki67 cell counts compared to Weissleder et al. are 
largely due to technical differences in the studies. Notably, Weissleder et al. used 
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thicker 50µm thick sections as opposed to 12µm used here, so their reports of 
higher cell counts are not unexpected. Marucci argues that studies using 
postmortem human brain tissue are likely to be strongly biased and suggests biopsy 
samples extracted from patients undergoing surgery for epilepsy as a better source 
of tissue for neurogenesis studies. Whilst it is acknowledged that any study using 
postmortem human brain will be a heterogeneous cohort, solely relying on ex vivo 
experiments, particularly from patients with conditions that are known to have 
dysregulated neurogenesis in animal models (Kralic et al., 2005) is inadequate to 
fully understand the extent of adult neurogenesis in the human brain. 
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Preamble 
 
Until recently and most notably through the work presented in Chapter 2, 
neurogenesis was postulated to have a role in neurological diseases. Given that 
hyposmia and memory deficits are associated with chronic alcoholism (Rupp et al., 
2003, Zucco et al., 2006) research has been directed towards investigating 
neurogenesis in ARBD. Although animal models of alcohol misuse show deficits in 
both SVZ (Hansson et al., 2010) and SGZ (Herrera et al., 2003) work in this 
laboratory found no difference in cell proliferation using PCNA as a proliferative 
marker in the SVZ of chronic alcoholics compared to age- and gender-matched 
controls (Sutherland et al., 2013). This study was pivotal in identifying many of the 
inconsistencies inherent in human neurogenesis research and ultimately led to the 
work presented in Chapter 2, it was noted during this study that a number of 
chronic alcoholics had PCNA+ cells throughout the grey matter (GM) and WM 
surrounding the SVZ. On further examination, these chronic alcoholics also had a 
pathological diagnosis of HE and accordingly this peculiar finding was further 
investigated. 
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3 Microglial proliferation in the brain 
of chronic alcoholics with Hepatic 
Encephalopathy 
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To Whom It May Concern,  
Faculty of Medicine  
University of Sydney  
 
Re: “Microglial proliferation in the brain of chronic alcoholics with hepatic 
encephalopathy.” Paper accepted by Metabolic Brain Disease December 2013 to 
be included as part of Claude Dennis’ Thesis.  
 
This is a letter to state the following authors contributions to this paper which will 
be submitted as part of Claude Dennis’ Thesis:  
 
CD – Study design, data acquisition, manuscript preparation.  
PS – Assisted with optimisation. Proof-reading and comments.  
MG – Assisted with neuropathology of microglia. Proof-reading and comments.  
DS – Clinical characterisation and provision of postmortem human brain tissue.  
JK – Study design, proof-reading and comments.  
GS – Study design and manuscript preparation. 
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4 An animal model of chronic 
Hepatic Encephalopathy 
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4.1 Introduction 
 
The work presented in the previous chapter demonstrated widespread microglial 
proliferation throughout the brains of a subset of chronic alcoholics with HE. Two 
major questions were left unanswered: i) what was causing microglial proliferation 
and ii) what did this mean clinically for these patients/did this reflect a beneficial or 
deleterious process? Studies in postmortem brain are incredibly valuable but 
inherently retrospective studies and clinical data may be limited and restricted to 
information provided by next of kin. Accordingly, animal models are warranted in 
combination with human studies for mechanistic studies. 
 
Currently there is no widely accepted model of HE and particularly for chronic 
forms of HE commonly classed as Type B or Type C. Whilst the pathogenesis of HE 
remains unknown, clearly a prerequisite for any model of HE is liver damage. 
Models of ALF rely on bile duct ligation (Jover et al., 2006, Wright et al., 2007a), 
end-to-side portocaval anastomosis (Jiang et al., 2009b, Jiang et al., 2009c) or by 
giving large doses of hepatotoxins such as TAA that leads to development of coma 
and death within days (Avraham et al., 2011, Farjam et al., 2012, Gomides et al., 
2014). However, HE is more often a chronic disease in humans and accordingly 
likely to have a different pathogenesis compared to the acute insult of rapidly 
developing liver failure. Accordingly, development of reliable chronic models is 
warranted. 
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Whilst liver damage is central in HE, there are many patients with varying degrees 
of liver damage that never suffer from encephalopathy. As HE is essentially a 
diagnosis of exclusion in humans, an obvious behavioural deficit indicative of 
encephalopathy is paramount in any model of HE. There are widely variable clinical 
symptoms of HE so there is no universally accepted behavioural test that is 
considered diagnostic of HE in animals. Previous studies have targeted different 
aspects of cognitive disturbances in HE such as motor function and exploration with 
open-field tests (Avraham et al., 2011, Avraham et al., 2009, Mendez et al., 2008), 
working memory using Y-mazes (Ding et al., 2015, Mendez et al., 2008) or spatial 
memory using the Morris Water Test (Dadsetan et al., 2016). Due to the broad 
nature of these tests no single behavioural deficit alone can warrant a diagnosis of 
HE in an animal but must be used in combination with other factors such as 
presence of liver disease, and presence of Alzheimer Type II astrocytosis in 
accordance with Butterworth et al.’s criteria (Butterworth et al., 2009). 
 
Considering astrocyte changes are classically viewed as the main pathological 
feature in HE, examination of the astrocytes is a useful tool when characterising a 
model. The appearance of At2a are the hallmark pathological feature of HE in the 
human brain (Kril and Butterworth, 1997) but is less well defined in current animal 
models with At2a usually only seen at coma stages of encephalopathy (Norenberg, 
1977) and often not reported in more recent models of HE (Ding et al., 2015, 
Rangroo Thrane et al., 2012, Rodrigo et al., 2010). An alternative to morphological 
features of astrocytes alone is immunohistochemical markers such as GFAP. GFAP 
expression is decreased in HE in humans (Kril et al., 1997a) with animal models of 
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hyperammonemia also showing decreases (Belanger et al., 2002) and portacaval 
anastomosis models demonstrating GFAP redistribution in the hippocampus 
(Suarez et al., 1998). 
 
Finally, HE is a complex disease and can arise as a result of liver failure of any 
aetiology. The patients themselves are also often complex with varying and 
sometimes co-morbid conditions such as alcohol misuse and NASH that may well 
contribute independently or synergistically to the development of HE. Accordingly, 
given there is currently no known single causative factor in HE a broad, multi-
factorial approach needs to be taken when attempting to model the disease. 
 
4.1.1 Aims 
 
To establish a mouse model of chronic HE with the same glial changes that are seen 
in humans. 
 
4.1.2 Hypotheses 
 
This chapter had five specific hypotheses: 
 
1. Chronic administration of TAA will cause irreversible liver injury. 
 
2. Chronic administration of TAA will impair spatial memory, motor function 
and emotionality consistent with Type C HE. 
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3. Chronic administration of TAA will cause a reduction in GFAP 
immunoreactivity in the DG. 
 
4. Chronic administration of TAA will cause microglial activation and 
proliferation in the DG. 
 
5. Co-administration of ethanol and/or HFD with TAA will exacerbate the signs 
of chronic HE. 
 
4.2 Methods 
 
4.2.1 Animal model of Liver failure, HFD and OH 
 
4.2.1.1 Animal Housing 
All animal work carried out here was approved by the Animal Ethics Committee of 
Sydney South West Area Health Service (Protocol No: 2008/1005). 75 BALB/c mice 
were obtained from the Animal Resource Centre (Perth, Australia) at five weeks old 
and maintained at the Animal Facility of Royal Prince Alfred Hospital. On arrival 
mice were housed in groups of 5-7 animals per cage with a 12-hour light/dark cycle 
in a room maintained at 22C. Each cage was then randomly assigned to one of the 
following groups: Chow, high-fat diet only (HFD), Ethanol only (OH), thioacetamide 
only (TAA), high-fat diet and ethanol (HFD + OH), high-fat diet and thioacetamide 
(HFD + TAA), ethanol and thioacetamide (OH + TAA), high-fat diet, ethanol and 
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thioacetamide (HFD + OH + TAA) (Table 4.1). Each group received their respective 
treatments for eight weeks as outlined below. Mice were weighed on the same day 
every seven days between 1400-1600h. 
 
Table 4.1 - Treatment Groups 
Treatment Number of Animals 
Chow n = 12 
HFD n = 6 
OH n = 7 
TAA n = 5 
HFD + OH n = 12 
HFD + TAA n = 11 
OH + TAA n = 10 
HFD + OH + TAA n = 12 
 
 
4.2.1.2 Feeding paradigm 
Each cage was fed ad libitum a diet consisting of either standard laboratory chow 
(Chow; 12% kCal fat content) or HFD prepared in-house using a formula based on 
rodent diet no. D12451 (HFD; 45% kcal fat, 20% kcal protein, 35% kcal 
carbohydrate, 0.25% cholesterol. D12451. Research Diets, New Brunswick, NJ, USA) 
(Rossmeisl et al., 2003, Surwit et al., 1995). 
 
 97 
4.2.1.3 Thioacetamide injections 
Mice received i.p. injections of TAA dissolved in 0.1M phosphate buffered saline 
(PBS) twice per week between 0800-0900 for the duration of the experiment. To 
avoid acute toxicity mice initially were given a dose of 100mg/kg for three weeks 
before increasing the dose to 200mg/kg for the remaining five weeks of the 
experiment. All cages not treated with TAA received a vehicle-only i.p. injection of 
0.1M PBS at the same time as the TAA injections were administered. 
 
4.2.1.4 Alcohol feeding protocol 
Chronic alcohol misuse consists of two patterns of drinking: Long-term 
consumption of high levels of alcohol and binge drinking. Here, a model consisting 
of both patterns of drinking was attempted. 
 
BALB/c mice are traditionally viewed as non-alcohol preferring animals (D'Souza El-
Guindy et al., 2010, Zhu et al., 2004) so here a two-bottle choice method was used 
to avoid fluid restriction and to increase ethanol intake (Spanagel and Holter, 1999, 
Tambour et al., 2008). As an adjunctive measure ethanol was supplemented with 
saccharin which has been reported to increase ethanol intake of BALB/c mice to 
levels similar to that of C57BL/6 (Bachmanov et al., 2002, Schweizer et al., 2009). 
Mice were initially acclimated for one week with a single bottle of tap water after 
which a second bottle of tap water was introduced for four days. At the 
commencement of the experiment one of the water bottles in each cage was 
replaced with 2% ethanol made up in distilled water with 0.2% saccharin. The 
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ethanol concentration was then increased every two days to 4%, 6%, 8% before 
remaining at 10%.  
 
To model a binge episode a deprivation method was initially used. Increased 
voluntary ethanol consumption following alcohol deprivation known as the alcohol 
deprivation effect (ADE) is a well-established phenomenon in rats (Koros et al., 
1999, Spanagel and Holter, 1999) however it is not as clear in mice. To assess if 
there is an ADE present in mice and to potentially increase ethanol doses alcohol 
was deprived for two days with cages having two bottles of tap water only during 
this period. This was performed twice, separated by six days with the standard 
water and 10% ethanol two-choice. 
 
As no ADE was seen in Ethanol cages, the experimental “binge” paradigm was 
altered. Instead of deprivation the ethanol cages received a direct “binge” by 
removing the water bottle and leaving a single bottle with 15% ethanol in the cage 
for two days.  
 
During the experiment, it was noticed that consumption of the ethanol + 0.2% 
saccharin solutions was decreasing as well as consumption of the water + 0.2% 
saccharin solutions in the non-ethanol cages. To counter the possibility that mice 
had developed a taste aversion to saccharin, saccharin was removed from both the 
ethanol and non-ethanol cages after five weeks for the remainder of the 
experiment (method outlined in Figure 4.1).  
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All bottles were weighed every two days between 1400-1500 and replaced with 
fresh solutions. Solutions were switched between sides every two days to avoid any 
side preference. Additionally, to account for spillage an empty cage was kept with 
an ethanol and water bottle and monitored simultaneously. Any fluid loss in these 
bottles was subtracted from the cage values to calculate daily intake.  
 
Figure 4.1 - Ethanol exposure paradigm. 
The schematic shows how animals were exposed to ethanol over the duration of 
the experiment. All cages were provided with two bottles and the solution in each 
bottle changed throughout the experiment. Initially animals were acclimatised to 
their cages with two bottles of tap water only followed by a weaning period of 
gradually increasing ethanol concentrations in one bottle. Following this, one bottle 
contained a regular 10% ethanol solution with 0.2% saccharin with periods of 
withdrawal (no ethanol bottle) and binge (15% ethanol only). After day 40 saccharin 
was removed from the ethanol solutions. 
 
 
4.2.2 Behavioural Testing 
As mice are crepuscular animals, time of day can influence behaviour and increase 
sensitivity of behavioural testing in certain strains of mice (Brown et al., 2000, 
Hossain et al., 2004, Roedel et al., 2006). Accordingly, all behavioural testing was 
performed during the active dark-phase between 1900-0000h in a room lit with a 
single lamp. Prior to testing, cages were bought into the testing room along a dark 
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corridor and allowed to acclimatise for 30-60 minutes. Open-field testing was 
performed on all animals over three evenings followed by Y-Maze testing over two 
evenings. 
 
4.2.2.1 Y-Maze 
Spatial memory was assessed using a custom-built Perspex Y-maze consisting of 
three identical arms (300mm x 100mm x 50mm) with even lighting of 8-10 lux in 
each arm (Appendix 1). Animals were then tested individually by placing them at 
the end of one arm and then allowing them to freely explore the maze for three 
minutes with their movement recorded from above by a webcam. After removal 
from the maze animals were placed in a holding cage separated from animals in 
their home cage that had not been tested and the maze thoroughly cleaned with 
80% alcohol between trials. Spontaneous alternation is defined as the percentage 
of “correct” arm entries and was scored manually from video recordings. Scoring 
started after the animal had entered two arms and was then scored as making 
either the “correct” or “incorrect” choice. If an animal chose an arm it had not 
entered on the previous two attempts it made the “correct” choice, if it returned 
down an arm it had entered on the previous two attempts it made the “incorrect” 
choice (Figure 4.2). This was converted to a percentage of spontaneous alternation 
based on the number of “correct” choices and the total arm entries. An arm entry 
was defined as both hind limbs crossing the threshold of an arm.  
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Figure 4.2 - Y-Maze 
A cartoon depicts how the Y-maze was used in behavioural studies. Mice were 
placed at the end of a start arm, once they had proceeded down a second arm the 
testing was started and they could make two choices. The “correct” choice was an 
arm they had not previously been down and the “incorrect” was the arm they had 
entered on the previous attempt. The number of “correct” and “incorrect” choices 
were recorded and spontaneous alternation (percentage of correct choices) 
calculated. 
 
4.2.2.2 Open-Field Test 
Open-field testing was performed in a custom-built black perspex box (400mm x 
400mm x 200mm) with even lighting of 6-12 lux in each corner. Animals were 
placed in the centre of the arena one at a time and allowed to freely explore the 
arena for five minutes. Their activity was recorded using a webcam fixed above the 
arena and faecal boli counted manually after the animal was removed. After 
testing, animals were placed in a holding cage that was separate from the animals 
in their home cage that had not been tested. The arena was thoroughly cleaned 
with 80% ethanol and allowed to dry between tests. Movement was analysed using 
TopScan software (CleverSys Inc., Reston, VA, USA) with an automatically generated 
centre zone defined as 50% of the arena’s surface area. The following measures 
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were recorded: total distance travelled, distance travelled in centre, % of distance 
travelled in centre, time spent in centre, number of crosses into centre, time 
elapsed before first exit of centre, number of stops (travelling less than 20mm/s), 
time spent stopped, number of freezes (travelling less than 0.05mm/s) and time 
spent frozen. In some instances, the software was unable to track the animal for 
part of the test, when this occurred these videos were excluded from analysis. 
 
4.2.3 Tissue processing 
 
4.2.3.1 Organ Collection 
Mice were deeply anesthetized via inhalation with 4% isofluorane and euthanised 
by cardiopuncture and exsanguination. Brains were removed from the skull and 
placed on a chilled platform where they were dissected along the longitudinal 
fissure. One hemisphere was snap frozen in liquid nitrogen and the other placed in 
ice-cold 10% formalin for 24 hours then washed three times in tris-buffered saline 
(TBS) and stored at 4C in 0.1M TBS with 0.1% azide until sectioning. In addition, 
the liver, spleen and kidneys were collected, weighed and stored for future use. All 
organ weights except brains were normalised to body weight and presented as 
gram of tissue per 30g of body weight. 
 
Blood was collected by cardiopuncture into capillary tubes containing 3.2% citrate 
solution (Greiner Bio-One, Fisher Scientific) and spun in a centrifuge at 3000rpm for 
15min. Plasma was collected and diluted with PBS 1:2 and levels of aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) 
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and gamma glutamyl transferase (GGT) analysed externally at Royal Prince Alfred 
Hospital Chemical Pathology using a Roche Cobas analyser. 
 
4.2.3.2 Tissue Sectioning 
Prior to sectioning for immunohistochemistry and immunofluorescence, 
hemispheres were cryoprotected in 30% sucrose in 0.1M TBS with 0.1% azide 
overnight at 4C. The OBs were removed with a blade then the hemisphere 
sectioned coronally at 40m on a cryostat with serial sections collected in TBS in 
12-well plates. Accordingly, each well contained a series of coronal sections, each 
480m apart, spanning the entire mouse brain. Finally, sections were washed three 
times in 0.1M TBS and stored at 4C in 0.1M TBS with 0.1% azide until staining. 
 
4.2.4 Immunostaining 
 
4.2.4.1 Immunohistochemistry 
No antigen retrieval was required for Iba1 immunohistochemistry of mouse brains. 
For each case, a series of free-floating sections, each 480m apart, were placed in a 
12-well plate such that an entire series was stained under the same conditions. 
Sections were washed three times in 50% ethanol for 5 minutes with gentle 
agitation. All subsequent incubations were performed with gentle agitation. 
Sections were then incubated in 50% ethanol with 3% (v/v) hydrogen peroxide for 
30 minutes to quench endogenous peroxidase activity, rinsed with deionised water, 
then washed three times with 0.1M TBS (pH 7.4), for five minutes each. Sections 
were blocked with 10% normal horse serum (NHS; Gibco, Life Technologies 
 104 
Australia Pty Ltd., Mulgrave, Australia) in 0.1M TBS with 0.1% Triton-X-100 for 30 
minutes and incubated with Iba1 (1:5000, rabbit polyclonal; 019-19741, Wako Pure 
Chemicals, Osaka, Japan) overnight at 4°C.  
 
The following day, the sections were allowed to equilibrate to room temperature 
before being washed and incubated in a biotinylated anti-rabbit secondary 
antibody (Biotinylated Anti-Rabbit IgG (H+L); 1:200, Vector Laboratories, 
Burlingame, California, USA) for one hour. Sections were then rinsed with 0.1M TBS 
(pH 7.4), washed and incubated in an avidin-biotin-peroxidase complex (Vectastain 
Elite ABC, Universal, 1:100) for one hour. Putative immunoreactivity was visualised 
by incubating the sections in diaminobenzidine (DAB) in the presence of 5% 
hydrogen peroxide for 30 seconds, then rinsed twice with 0.1M TBS (pH 7.4). 
Sections were floated in 0.1M TBS (pH 7.4), mounted onto superfrostTM slides and 
left to dry at room temperature for at least 24 hours. The following day, the slides 
were dehydrated through graded alcohols and xylene then rehydrated to remove 
any remaining lipid content from the tissue. A haematoxylin counterstain was 
applied by staining sections in Harris’ haematoxylin for 30 seconds, briefly 
decolourised in acid alcohol then stained in Scott’s Blueing solution for 45 seconds. 
Finally, sections were dehydrated through graded alcohols and xylene then 
coverslipped using DPX mounting media. 
 
4.2.4.2 Immunofluorescence 
For each case, a series of free-floating sections, each 480m apart, were placed in a 
12-well plate such that an entire series was stained under the same conditions. 
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Sections were washed three times in 50% ethanol for five minutes with gentle 
agitation. All subsequent incubations were performed with gentle agitation. 
Sections were then rinsed with deionized water and washed once with 0.1M PBS 
(pH 7.4), for five minutes. Sections were blocked with 10% NHS (Gibco, Life 
Technologies Australia Pty Ltd., Mulgrave, Australia) in 0.1M PBS with 0.1% Triton-
X-100 for 30 minutes and incubated with GFAP (1:2000, rabbit polyclonal; Z0334, 
Dako, Denmark) overnight at 4°C.  
 
The following day sections were allowed to equilibrate to room temperature before 
being washed in PBS and incubated in a secondary antibody (1:200: AlexaFluor 488, 
donkey anti-rabbit IgG, A-11008) for 72 hours at 4°C. Sections were then rinsed, 
washed, floated in 0.1M PBS (pH 7.4), mounted onto SuperfrostTM slides and 
immediately coverslipped using ProLong Diamond Antifade with 4’,6-diamidino-2-
phenylindole (DAPI; P36971, ThermoFisher, Massachusetts, USA). Slides were 
stored in the dark at room temperature for 48 hours hidden before imaging. 
 
4.2.5 Image Analysis 
 
4.2.5.1 Quantification of Iba1 
To determine Iba1 immunoreactivity, semi-automated analysis was performed on 
Iba1-stained coronal sections. Iba1 immunoreactivity was quantified in the caudate 
putamen, globus pallidus, prefrontal cortex, CA1, CA2/3 regions and the DG. Allen’s 
Mouse Coronal Brain Atlas was used as an anatomical reference for brain regions 
(Allen Institute for Brain Science, 2004). The prefrontal cortex was defined 
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according to Van De Werd and colleagues as the anterior cingulate, prelimbic, 
medial orbital and frontal areas (Van De Werd et al., 2010). This encompassed 
cortex anterior to the appearance of the hippocampal formation and medial to the 
cingulate bundle. 
 
 One series of Iba1-stained sections from each case were imaged at 200x 
magnification on a slidescanner (Zeiss AxioScan Z.1) then exported as jpg images 
with 50% size reduction. These images were then imported into FIJI software v2.0 
(Schindelin et al., 2012) and regions of interest outlined using the “freehand 
selection” tool. Four to six sections from each brain region were analysed rostral to 
caudal for each case. Colour deconvolution was then run before applying a fixed 
threshold to determine percentage of area stained. To determine optimal threshold 
a pilot study of ten randomly selected cases was performed. Initially each case was 
scored semi-quantitatively for the amount of staining visually then a threshold 
applied by a blinded observer (CD). The threshold that most suitably reflected the 
semi-quantitated scores was then applied for the experiment. 
 
To run this quantification protocol the following macro was applied after manually 
selecting regions of interest: 
 
run("Colour Deconvolution", "vectors=[H DAB]"); 
waitForUser; 
setAutoThreshold("Default"); 
setThreshold(0, 160); 
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run("Convert to Mask"); 
run("Measure"); 
 
4.2.5.2 Stereological quantification of microglia in dentate gyrus 
Prior to counting Iba1 stained sections a pilot study was conducted to determine 
optimal stereological parameters. Sections were placed on a motorised stage of an 
Olympus BX53 microscope equipped with StereoInvestigator (v5.65, MBF 
BioSciences) and regions of interest were outlined using a 4x objective. Initially the 
region was oversampled to get an accurate measure of the cell population, then 
counts were repeated on the same region using varying x, y step sizes and 
magnifications to determine which parameters were optimal for counting (Table 
4.2).  
 
Table 4.2 - Stereological Parameters for Iba1 Counts 
Magnification Counting 
Frame 
(m2) 
x, y step 
length (m) 
Iba1+ 
cells/mm2 
Iba1- 
cells/mm2 
% Iba1+  
1000x 2500 50 0 0 0 
1000x 2500 100 -21.9 +435.3 -0.37 
1000x 2500 200 +22.2 +1100 -0.60 
400x 10000 750 -202.7 -475 -3.34 
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Using the results from the pilot study the following method was used. The DG was 
outlined at 4x magnification in every section it was present in. This provided 
sampling at a number of locations rostral to caudal. Once outlined, each region was 
randomly sampled using the optical dissector probe at 1000x magnification under 
oil immersion with a 50 x 50m counting frame and 200m x, y step length. The 
inclusion criteria for a cell was having a clearly defined nucleus within the counting 
frame or crossing either the upper or right border of the counting frame (Figure 
4.3A). The exclusion criteria were a nucleus entirely outside the counting frame or 
any part of the nucleus crossing the left or lower border of the counting frame 
(Figure 4.3B). Any obvious endothelial cells or Iba1+ nuclei within blood vessels 
were excluded. 
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Figure 4.3 - Counting frame for Iba1 Stereological Quantification.  
Photomicrographs show Iba1 immunostained sections of dentate gyrus with a 50 x 
50 m counting frame digitally superimposed. Any Iba1+ nuclei that crossed the 
upper or right hand border (A) or was wholly within the counting frame (B, arrows) 
were counted. Cells with nuclei outside or crossing the left or lower border (B, 
arrowhead) were not included in the count. 1000x magnification. 
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4.2.5.3 GFAP image analysis of dentate gyrus 
Immunofluorescently-stained serial sections were used for GFAP analysis. To 
maximise consistency, the staining runs were limited to 12 cases at a time, with one 
case stained and quantified in all runs to validate consistency between staining 
runs. Once stained, each section was imaged using a slidescanner (Zeiss AxioScan 
Z.1). Images were then exported as .tiff files using Zen software with a 50% resize 
and Lempel-Ziv-Welch (LSW) lossless compression with minimum pixel value set to 
“2126” and maximum “30154”. 
 
To determine the percentage of area stained for each region, images were 
imported into FIJI software v2.0 (Schindelin et al., 2012). Regions of interest were 
outlined on DAPI only images with the freehand selection tool using Allen’s Mouse 
Coronal Brain Atlas as an anatomical reference for brain regions (Allen Institute for 
Brain Science, 2004, Lein et al., 2007). As a series of sections were stained, all 
sections where the structure of interest was present were analysed thus providing a 
rostral to caudal estimation of the entire structure. For the DG, this equated to 5-6 
sections per case. Once outlined, a custom-built macro was run on the 488 channel 
to convert the images to 8-bit, a threshold was set with a minimum pixel value of 
20 and maximum of 255, with the images then converted to a binary mask and 
percentage of area stained measured (Figure 4.4). The following code was used to 
run this macro: 
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 run(“8-bit); 
 
 setThreshold(20,255); 
 
 run(“Convert to Mask”); 
 
 run(“Measure”); 
 
 
A mean value of percentage of area stained was then calculated based on all 
sections of DG within a series. 
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Figure 4.4 - GFAP quantification.  
Slide scanner images of GFAP immunostained sections show the dentate gyrus 
digitally outlined in the 405nm (Blue, DAPI) (A) and 488nm (Green, GFAP) channel 
(B) with the corresponding thresholded binary image (C). Higher magnification of 
the dentate gyrus outlined on the 488 channel (D) and the corresponding high-
power thresholded binary image (E). 
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4.2.6 Statistical Analysis 
Statistical analyses were performed using the software package GraphPad Prism 7 
(v7.0a, GraphPad Software, Inc. 2016). Data outliers were removed using the ROUT 
method (Motulsky and Brown, 2006) with False Discovery Rate set to 1%. 
 
For intergroup differences, a One-Way Analysis of Variance (ANOVA) was initially 
performed on groups receiving a single treatment only (Chow, HFD, OH and TAA) 
with intergroup differences assessed using Tukey’s Post Hoc test. Although three 
treatment groups were used here, the experiment had an unbalanced design and 
therefore three-way ANOVA was inappropriate. Accordingly, potential interactions 
between treatments were assessed with a series of two-way ANOVAs. 
 
Potential changes in continuous variables such as body weight and intake of 
solutions over time were investigated using linear regression. An alpha value of 
0.05 was chosen as statistical significance for all tests. 
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4.3 Results 
 
Groups that received multiple treatments are indicated here by a “+” such as HFD + 
TAA whereas groups receiving a single treatment are described just as HFD or TAA. 
 
4.3.1 Animal Weights 
Survival across the majority (5/8) of the groups was 100%. Two animals each from 
the TAA and OH + TAA groups died shortly after their first TAA injection but the 
remainder survived until completion of the experiment. One animal in the TAA 
group died in week five of the experiment (Figure 4.5A). No obvious cause of death 
was identified by gross necroscopy. 
 
The mean animal weight in all groups increased over time except for the HFD + 
TAA, OH + TAA and HFD + OH + TAA groups which had negligible weight gain over 
the experiment. HFD and HFD + OH gained weight more rapidly than animals in the 
Chow group whilst the OH group showed a similar pattern of weight gain to Chow-
only (control). TAA increased their bodyweight but at a slower rate than Control 
(Figure 4.5B). 
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Figure 4.5 – Survival and body weight over time.  
(A) A Kaplan-Meier survival curve shows the percentage survival of 77 animals 
divided randomly into separate treatment groups. (B) A line graph shows mean 
bodyweights ± standard deviation of the eight treatments groups over eight weeks.  
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Initially, to assess the effects of single treatments, a one-way ANOVA was 
performed on the control, HFD, OH and TAA groups only. There was a significant 
difference across the groups (F(3,25) = 44.34, p<0.0001), and Tukey’s post-hoc 
comparison showed that HFD animals had a significantly greater body weight than 
all other groups whilst TAA was significantly lower than all groups except for OH (p 
= 0.06). There was no difference between control and OH (p = 0.62) (Figure 4.6A).  
 
In order to determine potential latent effects or interactions between HFD, OH and 
TAA, a series of two-way ANOVAs were performed (Table 4.3). There was a 
significant effect of TAA in both the OH and TAA (F(1,29) = 22.05, p<0.0001) (Figure 
4.6B) and HFD and TAA analyses (F(1,29) = 117.4, p<0.0001) (Figure 4.6C). Both 
analyses showed a significantly lower body weight in groups receiving TAA 
compared to those that did not. HFD-fed groups had a significantly higher body 
weight compared to Chow-fed in both the HFD and TAA analysis (F(1,29) = 28.54, 
p<0.0001) (Figure 4.6C) as well as the HFD and OH analysis (F(1,32) = 73.53, 
p<0.0001) (Figure 4.6D). Additionally there was a significant interaction between 
HFD and TAA (F(1,29) = 28.54, p<0.0001). Groups receiving OH had a significantly 
lower body weight than those receiving water in the HFD and OH analysis only 
(F(1,32) = 20.3, p<0.0001) and there was also an interaction between HFD and OH 
(F(1,32) = 8.572, p = 0.0062) (Figure 4.6D). 
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Figure 4.6 - The effect of high-fat diet, thioacetamide and alcohol on body weight. 
(A) A histogram shows the mean body weight of groups receiving a single treatment 
of either Chow (n = 11), OH (n = 7), HFD (n = 6) or TAA (n = 5). (B - D) Box and 
whisker plots of bodyweights in groups receiving combinations of treatments 
including (B) TAA and OH (n = 10) (C) TAA and HFD (n = 11) or (D) OH and HFD (n = 
12). (A) One-way ANOVA with Tukey’s Post-Hoc comparison. (B-D) Two-way 
ANOVAs. ** = p <0.01. **** = p < 0.0001. # = significant interaction. 
 
 
Table 4.3 - Summary of treatment effects on body weight 
  Main Effect   
Two-Way 
ANOVA HFD OH TAA Interaction 
OH + TAA   n.s. ⬇ n.s. 
HFD + TAA ⬆   ⬇ Yes 
HFD + OH ⬆ ⬇   Yes 
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4.3.2 Ethanol Intake 
 
4.3.2.1 Monitoring over time 
All cages with an ethanol bottle consumed ethanol throughout the experiment. 
There was no significant change in the percentage of ethanol solution consumed 
(relative to volume of water) per day in any of the groups (Figure 4.7A). However 
there was a significant decrease in the ethanol dose ingested per day although this 
was only in the OH-only group (F(1,12) = 10.07, p=0.008, R2=0.46) (Figure 4.7B). 
There was no difference in ethanol dose before and after removal of saccharin in 
any of the cages. Similarly, there was no difference in ethanol before (1.05  
1.2g/kg/day) and after (1.82  2.06) withdrawal periods (p = 0.25). 
 
The percentage intake of the saccharin solution decreased in the Chow 
(F(1,8)=22.82, p=0.001, R2=0.74) and HFD (F(1,8)=11.26, p=0.01, R2=0.59) groups 
but not in the TAA and HFD + TAA groups (Figure 4.7C). Furthermore, the volume of 
saccharin solution drunk by each cage decreased in the Chow (F(1,8)=31.3, 
p=0.0005, R2=0.80) and HFD + TAA (F(1,8)=10.65, p=0.01, R2=0.57) groups but not 
the HFD or TAA groups (Figure 4.7D).  
 
Total fluid intake (ethanol or saccharin + water) was consistent in all groups except 
the HFD + OH + TAA group that increased over time (F(1,13)=8.2, p = 0.01, R2=0.75) 
(Figure 4.7E). Mean daily water intake increased over time in the Chow 
(F(1,13)=38.51, p < 0.0001, R2=0.75), TAA (F(1,13)=5.32, p = 0.04, R2=0.29) and HFD 
+ TAA groups (F(1,13)=23.1, p = 0.0003, R2=0.64) (Figure 4.7F).  
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Figure 4.7 – Bottle intake over time.  
A series of line graphs shows the intake of different solutions over time for 
treatment groups given a two-bottle choice consisting of one bottle of water and 
one bottle of either ethanol (A and B) or saccharin solution (C and D). Data are 
expressed as percentage intake relative to total daily fluid intake including water (A, 
C) or intake adjusted for body weight (B, D-F).  
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Two-way ANOVA of HFD and TAA showed no difference in mean daily ethanol dose 
(Figure 4.8A) or mean daily percentage intake of the ethanol solution (Figure 4.8B) 
however an interaction between HFD and TAA was noted (F(1,100) = 4.162, p = 
0.044).  
 
Total water intake was monitored to account for any dehydration or avoidance. 
Mean daily water intake was significantly higher in groups receiving TAA (2.11  
0.67g/day/30g) compared to no TAA (1.83  1.00) in the HFD and TAA analysis only 
(F(1,86) = 7.283, p = 0.008) (Figure 4.8D). HFD-fed groups had a significantly lower 
water intake compared to Chow-fed in both HFD and TAA (F(1,86) = 11.43, p = 
0.001) analysis (Figure 4.8D) as well as HFD and OH (F(1,85) = 14.4, p = 0.0003) 
(Figure 4.8E). Additionally, mean daily fluid intake was monitored (water plus 
saccharin or alcohol solution) and showed identical trends to water intake (Figure 
4.8F-H). 
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Figure 4.8 – Comparison of ethanol and water intake in high-fat diet, 
thioacetamide and alcohol fed animals. 
 
Histograms show mean daily ethanol (A) dose and (B) percentage of total fluid 
intake. Box and whisker plots of water intake (C-E) and total fluid intake (F-H) for 
groups receiving combinations of treatments including OH and TAA (C, F), HFD and 
TAA (D, G) and HFD and OH (E, H). All analyses are two-way ANOVA. * = p < 0.05. ** 
= p <0.01. *** = p < 0.001. **** = p < 0.0001. 
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4.3.3 Organ weights 
4.3.3.1 Brain 
The analysis of the single treatment groups showed a significant variation across 
the groups (F(1,24) = 3.867, p = 0.02) however Tukey’s post-hoc comparison found 
no significant difference between any of the groups (Figure 4.9A). The comparison 
closest to significance was Chow vs TAA (p = 0.054). 
 
There was a significant decrease in brain weight in TAA-treated groups (0.42  
0.01g) compared to no TAA (0.43  0.01g) in the OH and TAA analysis only (F(1,28) 
= 14.66, p = 0.0007) (Figure 4.9B). There was also a significant decrease in HFD-fed 
groups (0.42  0.02g) compared to Chow-fed (0.43  0.01g) in the HFD and OH 
analysis (F(1,30 = 5.23, p = 0.03) (Figure 4.9D). 
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Figure 4.9 - The effect of high-fat diet, thioacetamide and alcohol on brain weight.  
(A) A histogram shows brain weights in groups receiving a single treatment only of 
either Chow (n = 11), OH (n = 7), HFD (n = 6) or TAA (n = 5). (B - D) Box and whisker 
plots of brain weights in groups receiving combinations of treatments including (B) 
TAA and OH (n = 10) (C) TAA and HFD (n = 11) or (D) OH and HFD (n = 12). (A) One-
way ANOVA. (B-D) Two-way ANOVAs. * = p < 0.05. ** = p <0.01. 
 
4.3.3.2 Liver 
There was significant variation in adjusted liver weight across the single treatment 
groups (F(3,25) = 24.44, p < 0.0001) with all four groups different to each other. OH 
(1.18  0.04g) and HFD (1.06  0.06g) had significantly lower liver weight than Chow 
(1.29  0.11g) whilst TAA was significantly higher (1.44  0.06g) (Figure 4.10A). 
 
When co-treatments were considered, TAA-treated groups also had a significantly 
higher adjusted liver weight compared to no TAA in both the OH and TAA (F(1,29) = 
49.29, p < 0.0001) (Figure 4.10B) and HFD and TAA analyses (F(1,30) = 71.89, p < 
0.0001) (Figure 4.10C). Additionally there was an interaction between HFD and TAA 
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(F(1,30) = 6.536, p = 0.02). HFD-fed groups however had a significantly lower 
adjusted liver weight compared to Chow-fed in both the HFD and TAA (F(1,30) = 
6.536, p = 0.02) (Figure 4.10C) and HFD and OH (F(1,32) = 11.31, p = 0.002) (Figure 
4.10D). Whilst there was no significant effect of OH there was an interaction 
between HFD and OH (F(1,32) = 26.05, p < 0.0001). 
 
 
Figure 4.10 - The effect of high-fat diet, thioacetamide and alcohol on liver 
weight.  
(A) A histogram of liver weights adjusted according to body weight in groups 
receiving a single treatment of either Chow (n = 11), OH (n = 7), HFD (n = 6) or TAA 
(n = 5). (B - D) Box and whisker plots of adjusted liver weights in groups receiving 
combinations of treatments including (B) TAA and OH (n = 10) (C) TAA and HFD (n = 
11) or (D) OH and HFD (n = 11). (A) One-way ANOVA. (B-D) Two-way ANOVAs. $, % 
and ^ = statistically significant difference to all other groups. * = p < 0.05. ** = p 
<0.01. *** = p <0.001. # = statistically significant interaction. 
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4.3.3.3 Spleen 
One-Way ANOVA of single treated groups showed a significant variation in adjusted 
spleen weight across the groups (F(3,25) = 10.56, p = 0.0001) with Tukey’s post-hoc 
comparisons showing significantly higher adjusted spleen weight in the TAA group 
only (Figure 4.11A).  
 
TAA-treated groups had a significantly higher adjusted spleen weight in both the 
OH and TAA (F(1,29) = 24.26, p < 0.0001) (Figure 4.11B) and HFD and TAA analyses 
(F(1,29) = 49.33, p < 0.0001) (Figure 4.11C). Groups receiving OH had a significantly 
lower adjust spleen weight groups (0.121  0.02g) compared to H2O groups (0.124 
 0.03g) in the OH and TAA analysis only (F(1,29) = 4.2, p = 0.049). Additionally, 
there was an interaction between OH and TAA (F(1,29) = 4.3, p = 0.047) (Figure 
4.11B). 
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Figure 4.11 - The effect of high-fat diet, thioacetamide and alcohol on spleen 
weight.  
(A) A histogram of spleen weights adjusted according to body weight in groups 
receiving a single treatment of either Chow (n = 11), OH (n = 7), HFD (n = 6) or TAA 
(n = 5). (B - D) Box and whisker plots of adjusted spleen weights in groups receiving 
combinations of treatments including (B) TAA and OH (n = 10) (C) TAA and HFD (n = 
11) or (D) OH and HFD (n = 12). (A) One-way ANOVA. (B-D) Two-way ANOVAs. * = p 
< 0.05. *** = p <0.001. # = statistically significant interaction. 
 
 
4.3.3.4 Kidney 
One-Way ANOVA of single treated groups showed a significant variation in adjusted 
kidney weight across the groups (F(3,25) = 17.53, p < 0.0001) with a Tukey’s post-
hoc comparison showing a lower adjusted kidney weight in the HFD group only 
(Figure 4.12A).  
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TAA-treated groups had lower adjusted kidney weight (0.49  0.03g) compared to 
no TAA (0.50  0.02g) in the OH and TAA analysis only (F(1,31) = 4.47, p = 0.04) 
(Figure 4.12B). HFD-fed groups also had significantly lower adjusted kidney weight 
compared to Chow-fed groups in both the HFD and TAA (F(1,31) = 19.88, p = 
0.0001) (Figure 4.12C) and HFD and OH analyses (F(1,33) = 59.63, p < 0.0001) 
(Figure 4.12D). There was an interaction between HFD and TAA (F(1,31) = 22.93, p < 
0.0001). 
 
 
Figure 4.12 - The effect of high-fat diet, thioacetamide and alcohol on kidney 
weight.  
(A) A histogram shows kidney weights adjusted according to body weight in groups 
receiving a single treatment of either Chow (n = 11), OH (n = 7), HFD (n = 6) or TAA 
(n = 5). (B - D) Box and whisker plots of adjusted kidney weights in groups receiving 
combinations of treatments including (B) TAA and OH (n = 10) (C) TAA and HFD (n = 
11) or (D) OH and HFD (n = 12). (A) One-way ANOVA. (B-D) Two-way ANOVAs. * = p 
< 0.05. ** = p <0.01. *** = p <0.001. # = statistically significant interaction. 
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Table 4.4 - Summary of Organ Weights. 
    Main Effect   
Parameter 
Two-Way 
ANOVA 
HFD OH TAA Interaction 
Brain 
OH + TAA   n.s. ⬇ n.s. 
HFD + TAA n.s.   n.s. n.s. 
HFD + OH ⬇ n.s.   n.s. 
Liver 
OH + TAA   n.s. ⬆ n.s. 
HFD + TAA ⬇   ⬆ Yes 
HFD + OH ⬇ n.s.   Yes 
Spleen 
OH + TAA   ⬇ ⬆ Yes 
HFD + TAA n.s.   ⬆ n.s. 
HFD + OH n.s. n.s.   n.s. 
Kidney 
OH + TAA   n.s. ⬇ n.s. 
HFD + TAA ⬇   n.s. Yes 
HFD + OH ⬇ n.s.   n.s. 
 
 
4.3.3.5 Non-adjusted Organ Weights 
Adjusted weights were used for all organs except the brain. Analyses of raw organ 
weights showed similar results to those presented above however given the 
experimental paradigm, adjusted weights were considered the more reliable 
dataset (Table 4.5). 
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4.3.4 Macroscopic liver pathology 
Gross macroscopic pathological assessment of the liver showed changes in groups 
receiving TAA. Chow-fed animals had dark livers with a smooth, glossy surface. 
Animals receiving a combination of HFD + OH had slightly paler livers but retained a 
smooth surface. All groups that had received TAA regardless of whether in 
combination or alone were paler in colour and had clear nodularity of the liver 
surface (Figure 4.13). Pathological assessment was not performed on the HFD or OH 
group. 
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Figure 4.13 - Macroscopic liver pathology in animals treated with a high-fat diet, 
thioacetamide and alcohol. 
A series of photographs show whole livers recovered from animals receiving various 
treatments. The liver of a Chow-only animal displays a smooth, glossy surface and a 
similar appearance to an animal receiving HFD + OH (Top left and middle). All 
animals that had received TAA injections had enlarged livers with nodular surfaces 
(Upper right and bottom panel). Photographs not to scale. 
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4.3.5 Liver function tests 
One-Way ANOVA of single treatment groups showed a significant variation across 
the groups for AST (F(3,25) = 131.7, p < 0.0001) (Figure 4.14A), ALT (F(3,23) = 188.9, 
p < 0.0001) (Figure 4.14B), ALP (F(3,24) = 65.07, p < 0.0001) (Figure 4.14C), and 
AST:ALT (F(3,24) = 13.71, p < 0.0001) (Figure 4.14D). Tukey’s post-hoc comparisons 
showed that TAA was significantly higher than the other groups for AST, ALT and 
ALP and significantly lower than all other groups for AST:ALT. 
 
Two-way ANOVA of all groups showed TAA as the main effect in all analyses with 
significantly higher levels of AST, ALT and ALP compared to no TAA and significantly 
lower AST:ALT. There was an interaction between HFD and TAA for AST (F(1,30) = 
10.64, p = 0.0028) (Figure 4.14E) and ALT(F(1,28) = 8.699, p = 0.0064) (Figure 4.14F) 
but not ALP or AST:ALT. 
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Figure 4.14 – The effect of high-fat diet, thioacetamide and alcohol on liver 
function tests.  
Histograms show (A) AST, (B) ALT, (C) ALP and (D) AST:ALT ratio of groups receiving 
a single treatment of either Chow (n = 11), OH (n = 7), HFD (n = 6) or TAA (n = 5). 
Box and whisker plots of (E) AST and (F) ALT of groups receiving a combination of 
HFD and TAA (n = 11). (A-D) One-way ANOVAs. (E-F) Two-way ANOVAs. * = p < 0.05. 
*** = p <0.001. **** = p <0.0001. # = statistically significant interaction. 
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4.3.6 Behavioural Testing 
 
4.3.6.1 Y-Maze 
A Y-maze behavioural paradigm was used to examine spatial memory. One-way 
ANOVA of the four, single-treatment groups found no difference in either 
spontaneous alteration (F(3,25) = 1.52, p = 0.23) (Figure 4.15A) or total arm entries 
(F(3,25) = 0.71, p = 0.55) (Figure 4.15B). Similarly, two-way ANOVAs showed no 
difference across all groups for either spontaneous alteration or total arm entries. 
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Figure 4.15 – Spontaneous alteration and arm entries in a Y-maze.  
Scatterplots show spontaneous alteration (A) and total arm entries (B) for animals 
in a Y-Maze. One-way ANOVA showed no significant difference across the groups 
for either spontaneous alteration or total arm entries. Data expressed as mean  
standard deviation. 
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4.3.6.2 Open Field 
The Open-Field test was used test to assess motor function, exploration, anxiety 
and emotionality in laboratory animals (Bures et al., 1976, Gould et al., 2009). In 
addition to measures of movement the number of faecal boli are recorded as an 
indicator of autonomic nervous system activity and can be extrapolated to anxiety-
like behaviour (Crumeyrolle-Arias et al., 2014, Gould et al., 2009, Walsh and 
Cummins, 1976). 
 
One-way ANOVA of single-treatment groups showed no significant difference in 
distance travelled (F(3,25) = 0.65, p = 0.59), distance travelled in centre (F(3,25) = 
0.51, p = 0.51), time in centre (F(3,25) = 0.87, p = 0.47), percentage of distance 
travelled in centre (F(3,25) = 0.48, p = 0.70), number of times stopped (F(3,25) = 
0.16, p = 0.92) or total time stopped (F(3,25) = 0.18, p = 0.90). Similarly, the series 
of Two-Way ANOVAs showed no differences for these Open-Field parameters. 
 
4.3.6.2.1 Number of Freezes 
There was a significant difference in the ‘Number of Freezes’ across the single-
treatment groups (F(3,23) = 13.08, p < 0.0001) with Tukey’s Post-Hoc comparisons 
showing a significant increase in the number of freezes in TAA (31.6  9.9) and HFD 
(38.3  8.7) compared to either Chow (15.73  10.2) or OH (11  1.0). There was no 
difference between HFD and TAA or Chow and OH. (Figure 4.16A). 
 
To assess potential interactions between treatments, a series of two-way ANOVAs 
were performed on combination treated groups (Table 4.). There was a significant 
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increase in the ‘Number of Freezes’ in groups that had received TAA (marginal 
mean = 26.1  9.8) compared to no TAA (14.3  8.6) but only in the OH and TAA 
analysis (F(1,27) = 16.91, p = 0.0003) (Figure 4.16B). There was significantly more 
freezes in HFD-fed groups (24.6  14.1) compared to Chow-fed (14.3  8.6) in the 
HFD and OH analysis only (F(1,30) = 17.73, p = 0.0002) (Figure 4.16C). Finally, 
groups receiving OH (15.7  9.5) had significantly fewer freezes compared to H2O 
(23.7  14.6; F(1,30) = 13.18, p = 0.001). Additionally there was an interaction 
present between HFD and TAA (F(1,29) = 22.18, p<0.0001) as well as HFD and OH 
(F(1,30) = 13.18, p = 0.03) (Figure 4.16C). 
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Figure 4.16 - Number of freezes during an Open-Field Test in animals treated with 
high-fat diet, thioacetamide and alcohol.  
(A) A histogram shows the number of freezes during a five minute Open-Field test 
in groups receiving a single treatment of either Chow (n = 11), OH (n = 7), HFD (n = 
6) or TAA (n = 5). (B - D) Box and whisker plots of number of freezes in groups 
receiving combinations of treatments including (B) TAA and OH (n = 10) (C) TAA and 
HFD (n = 11) or (D) OH and HFD (n = 12). (A) One-way ANOVA with Tukey’s Post-Hoc 
comparison. (B-D) Two-way ANOVAs. ** = p <0.01. *** = p < 0.001. # = statistically 
significant interaction. 
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4.3.6.2.2 Crosses into Centre 
For ‘crosses into centre’ One-Way ANOVA of single treated groups showed no 
difference across the groups (F(3,24) = 3.006, p = 0.05) (Figure 4.17A). 
 
However, groups receiving TAA showed significantly fewer crosses (17.4  8.6) 
compared to no TAA (22.4  7.7) in the OH and TAA analysis (F(1,27) = 4.924, p = 
0.0351) (Figure 4.17B). HFD-fed groups also had significantly fewer crosses (16.1  
5.4) compared to Chow-fed groups (22.4  7.7) in the HFD and OH analysis (F(1,31) 
= 10.28, p = 0.003) (Figure 4.17D). 
 
Furthermore, time to outside was significantly longer for TAA although this was 
only seen in the TAA and HFD analysis.  
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Figure 4.17 - Crossing into centre in an open-field test in animals treated with 
high-fat diet, thioacetamide and alcohol.  
(A) A histogram shows the number of crosses into the centre during a five-minute 
open-field test in groups receiving a single treatment of either Chow (n = 11), OH (n 
= 7), HFD (n = 6) or TAA (n = 5). (B - D) Box and whisker plots of the number of 
crosses into centre in groups receiving combinations of treatments including (B) 
TAA and OH (n = 10) (C) TAA and HFD (n = 11) or (D) OH and HFD (n = 12). (A) One-
way ANOVA. (B-D) Two-way ANOVAs. * = p < 0.05. ** = p <0.01. 
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4.3.6.2.3 Faecal Boli 
One-way ANOVA of single-treated groups showed a significant difference for 
number of faecal boli across the groups (F(3,25) = 5.99, p = 0.003) with Tukey’s 
Post-Hoc comparison showing significantly fewer boli in the HFD group (2.5  1.1) 
compared to Chow (7  2.5) and TAA (7.8  2.5) but not OH (5.4  2.9) (Figure 
4.18A). 
 
TAA-treated groups also had a significantly higher number of faecal boli (6.4  5.4) 
compared to no TAA (5.4  3.0) in the HFD and TAA analysis (F(1,29) = 5.49, p = 
0.03) (Figure 4.18B). HFD-fed groups had significantly fewer faecal boli than Chow-
fed groups in both the HFD and OH (F(1,31) = 16.24, p = 0.0003) (Figure 4.18C) and 
HFD and TAA analyses (F(1,28) = 13.79, p = 0.0009) (Figure 4.18D). 
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Figure 4.18 – Number of Faecal Boli during an open-field test in animals treated 
with high-fat diet, thioacetamide and alcohol. 
(A) A histogram shows the number of faecal boli during a five minute open-field 
test in groups receiving a single treatment of either Chow (n = 11), OH (n = 7), HFD 
(n = 6) or TAA (n = 5). (B - D) Box and whisker plots of the number of faecal boli in 
groups receiving combinations of treatments including (B) TAA and OH (n = 10) (C) 
TAA and HFD (n = 11) or (D) OH and HFD (n = 12). (A) One-way ANOVA. (B-D) Two-
way ANOVAs. * = p < 0.05. ** = p <0.01. 
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Table 4.6 - Summary of Open-Field analyses 
    Main Effect   
Parameter Two-Way ANOVA HFD OH TAA Interaction 
Number of 
Freezes  
OH + TAA   n.s. ⬆ n.s. 
HFD + TAA n.s.   n.s. Yes 
HFD + OH ⬆ ⬇   Yes 
Crosses into 
Centre 
OH + TAA   n.s. ⬇ n.s. 
HFD + TAA n.s.   n.s. n.s. 
HFD + OH ⬇ n.s.   n.s. 
Faecal Boli 
OH + TAA   n.s. n.s. n.s. 
HFD + TAA ⬇   ⬆ n.s. 
HFD + OH ⬇ n.s.   n.s. 
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4.3.7 Iba1 
 
4.3.7.1 Unbiased Stereology 
There were no differences in mean Iba1+ cells/mm2 within the DG (F(3,22) = 2.01, p 
= 0.14) between any of the single-treatment groups. Similarly, there were no 
significant differences between co-treatment groups (Figure 4.19). 
 
 
Figure 4.19 - The effect test of high-fat diet, thioacetamide and alcohol on Iba1 
cell density in the dentate gyrus. 
(A) A histogram of the density of Iba1+ cells in the dentate gyrus in groups receiving 
a single treatment of either Chow (n = 11), OH (n = 7), HFD (n = 6) or TAA (n = 5). (B 
- D) Box and whisker plots of the density of Iba1+ cells from groups receiving 
combinations of treatments including (B) TAA and OH (n = 10) (C) TAA and HFD (n = 
11) or (D) OH and HFD (n = 12). (A) One-way ANOVA. (B-D) Two-way ANOVAs. 
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4.3.7.2 Percentage of area stained  
Whilst providing a sensitive measure of microglial activation and/or proliferation 
unbiased stereology is labour intensive and low-throughput. As no changes were 
seen in the DG a high-throughput, semi-automated, technique was used to screen 
other brain regions for broad changes to the activation state of microglia in single 
treatment groups only. 
 
There were no differences between single treatment groups in the caudate 
putamen (F(3,21) = 1.96, p = 0.15), globus pallidus (F(3,21) = 1.70, p = 0.20), DG 
(F(3,21) = 1.06, p = 0.39), CA1 (F(3,20) = 0.57, p = 0.64) or CA2/3 regions (F(3,20) = 
2.76, p = 0.07) (Figure 4.20). However, there was a significant difference in the 
prefrontal cortex (F(3,19) = 4.04, p = 0.02) where microglial activation in the OH 
group (mean = 263.5  140.4% of Chow) was greater than Chow (100  69.4; p = 
0.03) and HFD (82.04  52.3; p = 0.03) but not TAA (140.4  125.5; p = 0.79) (Figure 
4.20A). 
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Figure 4.20 –Iba1 immunostaining across various brain regions in animals treated 
with high-fat diet, thioacetamide and alcohol. 
Histograms show percentage of area stained with the microglial marker, Iba1 
relative to Chow in the (A) prefrontal cortex (B) Caudate putamen (C) Globus 
Pallidus (D) Dentate Gyrus (E) CA1 and (F) CA2/3. Data presented as mean  
standard deviation. One-way ANOVA: * = p < 0.05. Chow (n = 11), HFD (n = 6), OH (n 
= 7), TAA (n =5) 
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The morphology of the Iba1+ cells was heterogeneous, with variation not only 
between cases in the same treatment groups but also across different brain regions 
in a single animal. In the prefrontal cortex of the Chow group the majority of the 
cells were ramified with numerous, radially projecting thin branches (Figure 4.21A). 
This was also the predominant cell type in the HFD group (Figure 4.21B). In the OH 
group, both the nuclei and cytoplasm were more intensely immunopositive for 
Iba1+ than Chow. The processes were also radially projecting but had a more 
tortuous phenotype (Figure 4.21C). The TAA group had a similar phenotype to OH 
(Figure 4.21D). One animal in the Chow group had extensive microglial activation in 
the prefrontal cortex as well as other brain regions and was excluded from the 
analyses (See section 4.2.6). 
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Figure 4.21 – Microglial morphology in the prefrontal cortex of animals treated 
with high-fat diet, thioacetamide and alcohol.  
Photomicrographs of Iba1+ immunostaining of thick (40m) sections of the mouse 
prefrontal cortex treated with (A) Chow-only and (B) high-fat diet (HFD)- (C) (OH) 
(C) and (D) thioacetamide (TAA) injections (D). 100x magnification with 400x 
magnification insets. 
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4.3.8 GFAP percentage of area stained 
There were no differences in mean percentage of area stained with GFAP within 
the DG (F(3,25) = 1.04, p = 0.39) between any of the single-treatment groups. 
Similarly, there were no significant differences between co-treatment groups 
(Figure 4.22). 
 
 
Figure 4.22 - GFAP in the dentate gyrus of animals treated with high-fat diet, 
thioacetamide and alcohol. 
(A) A histogram of the percentage of area stained with GFAP in the dentate gyrus in 
groups receiving a single treatment of either Chow (n = 11), OH (n = 7), HFD (n = 6) 
or TAA (n = 5). (B - D) Box and whisker plots of the percentage of area stained with 
GFAP in groups receiving combinations of treatments including (B) TAA and OH (n = 
10) (C) TAA and HFD (n = 11) or (D) OH and HFD (n = 12). (A) One-way ANOVA. (B-D) 
Two-way ANOVAs. 
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4.4 Discussion 
 
The primary aim of this study was to model a chronic form of HE which replicated 
the clinical signs and symptoms of the disease as well as the microglial changes 
described here in postmortem human brain tissue (Dennis et al., 2014). The 
majority of previous animal work in HE has employed a model of acute disease 
using high dose hepatotoxins, with animals often becoming comatose and dying 
within days of administration (Farjam et al., 2012, Miranda et al., 2010, Rangroo 
Thrane et al., 2012).  
 
The major outcome of this work was that animals treated with TAA developed 
pathological and biochemical evidence of liver failure with hepatomegaly and 
macroscopic nodularity of the liver surface as well elevations of transaminases. 
Additionally, these animals had significant weight loss and a mild behavioural deficit 
detected in an Open Field Test. In contrast to the hypotheses there was no 
evidence of microglial anomalies. 
 
Chronic exposure to TAA induces direct liver injury but given the importance of 
chronic alcoholism or NASH in the clinical context of HE these factors were 
considered as alternatives or adjunctive to TAA per se. It is less clear whether 
combining OH and HFD mimicked current clinical scenarios as the reports on the 
relationships between chronic alcohol consumption and BMI vary (Addolorato et 
al., 2000, Lukasiewicz et al., 2005). The rapid rise of obesity in western societies 
suggests that this combination will become more common. Accordingly, this study 
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examined combinations of TAA, HFD and OH but these additional exposures in 
combination or alone showed no consistent additive relationships with TAA. 
 
4.4.1 Body weight is increased in high-fat diet and decreased in thioacetamide 
treated animals 
Animal body weight is used as a measure of general health. Body weight alone can 
be misleading due to development of anomalies such as tumours and more 
rigorous scoring systems can be used (Ullman-Cullere and Foltz, 1999) but it 
remains a useful gross measure of animal well-being. Here, all TAA-treated animals 
had lower body weights compared to non-TAA animals at the time of termination. 
As expected animals that received HFD had a higher body weight. 
 
4.4.2 Ethanol Intake 
Alcohol is a common causative factor of liver damage leading to HE and patients are 
often still consuming alcohol despite their liver disease. Here, all cages provided 
with an ethanol bottle consumed ethanol regularly throughout the experiment 
albeit at low levels. Accordingly, this was a model of chronic low-dose alcohol 
consumption. 
 
In the OH only cage the mean daily ethanol dose was 1.4g/kg/d and the mean 
ethanol percentage intake was 16.8% of total fluid intake. There was no difference 
compared to any other groups that received ethanol. This is substantially lower 
than values reported elsewhere of 12-18g/kg/day (Belknap et al., 1993, Yoneyama 
et al., 2008) although the relative percentage intake of ethanol solution here may 
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be more in line with levels reported elsewhere (Blizard et al., 2004). A notable 
difference between these previous studies and the present study is the chronicity 
of the model. These previous studies have examined alcohol consumption over 
three to four days only to calculate mean daily ethanol dose. Here the mean was 
obtained by taking measurements every two days for 42 days. Nevertheless, at no 
point in this experiment did ethanol doses go above 5g/kg/day even in the early 
stages.  
 
A problematic area with animal research into alcohol consumption is what reflects 
a physiologically relevant or comparable level of drinking to humans. Chronic 
alcohol use in humans is a complex phenomenon with periods of binging, 
abstinence, and withdrawal and therefore how this is best modelled in animals is 
subject to debate. Each of these components of chronic alcohol use may have 
different mechanistic roles in AUDs and potentially HE. The goal here was to have 
animals regularly drinking alcohol which was achieved. 
 
The most pertinent question to this study is whether this regular, low level 
consumption is sufficient to influence liver pathology and induce a phenotype 
consistent with HE. There were no effects from ethanol alone and no additive 
effects when TAA was supplemented with alcohol in terms of liver damage or 
behaviour. This may indeed reflect alcohol not having an effect on these measures, 
however a more likely scenario is that a high enough ethanol dose was not reached 
as alcohol has well known hepatotoxic properties that should induce pathological 
changes in the liver (Duly et al., 2015).  
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Methods of delivery of ethanol to laboratory animals varies widely from basic 
measures such as simply supplementing drinking water with ethanol through to 
invasive measures such as intragastric lavage (Duly et al., 2015). A major challenge 
here was delivering an adequate dose of ethanol to the animals given the strain of 
mouse used. BALB/c mice are generally considered a “non-alcohol preferring” strain 
with minimal voluntary consumption of ethanol (Kakihana and McClearn, 1963, Le 
et al., 1994). BALB/c animals were chosen for three main reasons: i) BALB/c have a 
higher susceptibility to toxic liver damage (Hillebrandt et al., 2002), (ii) there was an 
established model of HFD and pilot study data from TAA-induced liver damage 
available to guide experimental design in the centre where this work was carried 
out (Calabro et al., 2014, Farrell et al., 2014) and (iii) BALB/c mice are considered 
more user-friendly and were therefore more suitable for this large experiment that 
involved extensive animal handling. 
 
It was unknown how much ethanol animals would consume at the start of this 
experiment so a number of techniques were used with the main goal of maximising 
the dose animals were receiving. Titrating ethanol solutions up and offering a two-
bottle choice method had two advantages; it increases ethanol intake as well as 
avoiding potential confounding from dehydration due to animals avoiding a single 
bottle of ethanol (Blizard et al., 2004, Zhu et al., 2004, Belknap et al., 1993). 
Supplementing ethanol solutions with artificial sweeteners such as saccharin has 
also been suggested to increase ethanol consumption in non-alcohol preferring 
animals (Yoneyama et al., 2008). As the main aim here was to increase ethanol dose 
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and not to determine whether supplementing with saccharin increases alcohol 
consumption no comment can be made here as to whether the latter occurred. 
During the experiment, it was noticed that saccharin consumption was decreasing 
in cages with no ethanol. Studies that suggest the use of saccharin supplementation 
in ethanol solutions had short monitoring periods, some as brief as four days 
(Belknap et al., 1993, Yoneyama et al., 2008). With longer exposure to saccharin it 
has been suggested that the hedonic effects dissipate and a taste aversion may 
develop (Schweizer et al., 2009). Accordingly, in line with the primary goal of 
maximising ethanol dose, saccharin was removed from day 40. 
 
Another technique used to increase ethanol intake is the ADE where animals 
dependent on ethanol and then deprived will consume larger amounts when 
ethanol is reintroduced. This phenomenon is well established in rats but the effect 
is not currently as clear in mice (Koros et al., 1999, Spanagel and Holter, 1999, 
Tambour et al., 2008). No ADE was seen in the current study. Given the low 
baseline intake of ethanol here it is questionable whether these animals could be 
considered dependant on alcohol and as such no ADE would be expected. To 
continue with the main goal of maximising ethanol dose, withdrawal phases were 
replaced with “binge” phases from day 30 with a single bottle of 15% ethanol 
available although this did not significantly affect alcohol doses (data not shown). 
 
As there was uncertainty regarding the dose received and low volumes of ethanol 
consumed future studies may explore other methods of ethanol delivery. 
Intragastric lavage is a commonly used technique which is advantageous as a 
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known volume of alcohol is directly administered to each animal. This technique 
however is invasive and stress-inducing and not feasible for chronic administration 
of ethanol. Future studies may be better suited to using alternative alcohol feeding 
paradigms such as inhalation chambers or liquid diets. 
 
4.4.3 Macroscopic pathology 
The most prominent pathological changes were in the TAA-treated groups with 
hepatomegaly, elevations of the transaminases and nodularity of the liver surface 
on macroscopic examination. Interestingly, groups receiving HFD had smaller liver 
weights although no derangement of their liver function tests were evident. 
 
Hepatomegaly and nodularity are consistent with previous reports of TAA-induced 
liver damage (Honda et al., 2002). Additionally, given fibrotic changes are seen with 
single dose (Avraham et al., 2011, Miranda et al., 2010) or short courses of TAA 
administration (Rama Rao et al., 2014), it is likely that TAA animals here had liver 
damage throughout the time-course of the experiment. A clear limitation here is a 
lack of a microscopic pathological diagnosis but this is part of ongoing collaborative 
work.  
 
Elevations of transaminases, particularly ALT are strong indicators of a pathological 
process occurring in the liver. They are limited however as they cannot distinguish 
between different stages of liver disease such as steatosis (Hillebrandt et al., 2002) 
and fibrosis (Hillebrandt et al., 2002). Nodularity of the liver surface is a well-known 
feature of liver fibrosis and cirrhosis (Theise, 2015) and its presence here is strongly 
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indicative of a fibrotic process and possible cirrhosis. Without microscopic 
confirmation, an exact diagnosis cannot be made but the combination of 
hepatomegaly, macroscopic nodularity and deranged liver function tests are 
strongly suggestive that animals treated with TAA had considerable liver damage 
and therefore predisposed to developing some degree of HE. 
 
An unexpected but interesting finding was decreased brain weights in TAA-treated 
animals. Brain volume reaches a maximum and remains constant in mice from post-
natal day 20 (Chuang et al., 2011) and here treatments were started at seven weeks 
of age so any changes were unlikely to be due to developmental impairment but 
rather the result of treatments on the mature brain. There is a paucity of data on 
brain weights in models of HE and decreased brain weight is non-specific with 
widely varying aetiologies. Nevertheless, it is interesting to note that WM volume is 
decreased in human alcohol-related brain damage (Kril et al., 1997b) and is even 
more pronounced in patients with cirrhosis, Wernicke’s encephalopathy and 
Korsakoff’s psychosis (Kril, 1995). 
 
4.4.4 Behavioural Testing 
Behavioural phenotypes were explored as psychiatric disturbance is the major 
clinical feature of HE. In TAA-treated animals there were anomalies in the number 
of freezes and crosses into centre in an Open-Field test but there were no 
differences between the groups seen in the Y-maze. Interestingly, groups receiving 
HFD also showed changes in the number of freezes and crosses into centre as well 
as number of faecal boli in the Open-Field. 
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As this was a pilot study, behavioural tests needed to have a broad scope. The 
Open-Field test is useful due to its relative ease of use, high-throughput nature and 
ability to generate large amounts of data pertaining to a number of aspects of an 
animal behaviour including behaviours relevant to HE such as anxiety and motor 
function. The Y-maze, a test for spatial memory, was useful here as it has been 
previously used in models of HE (Ding et al., 2015) and allowed for comparison with 
these previous studies. 
 
4.4.4.1 Behavioural testing in models of HE 
One of the main difficulties with developing a model of HE is that it remains a 
diagnosis of exclusion and accordingly has a wide variety of symptoms. It is 
therefore difficult to choose an appropriate behavioural test or even battery of 
tests to reflect this neurological ‘potpourri’. The two behavioural tests used here 
are coarse measures of behaviour, designed to detect gross abnormalities so if 
subtle deficits were indeed present they may have not been detected by the tests 
employed here. Notably, the majority of previous studies describing behavioural 
changes in models of HE were in the acute period following the first dose of TAA 
(Avraham et al., 2011, Avraham et al., 2009, Gammal et al., 1990, Miranda et al., 
2010). Here, animals receiving TAA showed marked lethargy in the period following 
initial injections, but subsequently recovered well before behavioural tests were 
conducted. This was an observation only and no objective testing was done at this 
time to quantify the response. 
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4.4.4.2 Open-Field Test 
Open-Field tests yield large volumes of data, understanding and interpreting it 
however is complex with parameters of movement, non-movement, bowel motions 
and others all able to be interpreted as due to mechanical, cognitive, neurological 
or emotional causes and beyond. Notwithstanding this, the Open-Field test is a 
well-validated test of anxiety in laboratory animals (Carola et al., 2002, Bailey and 
Crawley, 2009) although interpretation can vary depending on the experimental 
paradigm.  
 
The number of freezes and crosses into the centre of an arena are often viewed as 
measure of emotionality in an animal, particularly anxiety and fear (Gould et al., 
2009). Here there was increased number of freezes and fewer crosses into the 
centre in groups receiving TAA as well as groups receiving HFD. This suggests 
increased anxiety-like behaviours in animals with liver damage in the case of the 
TAA animals which may well reflect some of the psychiatric symptoms present in 
human HE. Notably, this may also reflect a motor deficit in these animals however 
given that there was no difference in total distance travelled it seems unlikely to be 
due to a primary mechanical issue. Increased anxiety-associated behaviours in 
animals receiving HFD was unexpected but interesting. Furthermore, animals 
receiving HFD produced fewer faecal boli in the open-field, another phenotype 
attributed to anxiety (Crumeyrolle-Arias et al., 2014) but probably more useful as 
an indicator of autonomic nervous system function (Gould et al., 2009, Walsh and 
Cummins, 1976). 
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This finding of anxiety-like behaviour in TAA-treated animals is at odds with 
previously reported motor function impairment in acute TAA-induced fulminant 
hepatic failure (Avraham et al., 2011, Avraham et al., 2009) and no behavioural 
deficit at all in animals that received 12 weeks of TAA supplementation in their 
drinking water (Mendez et al., 2008). Clearly, acute fulminant hepatic failure 
represents a different paradigm to that presented here so a different behavioural 
phenotype is expected. Inconsistencies with another chronic model of TAA 
(Mendez et al., 2008) however are likely due to lower doses in TAA 
supplementation of water compared to i.p. injections. Given liver pathology was 
not reported by Mendez et al. this low dose of TAA may well not have led to the 
significant liver injury that was associated with increased anxiety behaviours 
reported here. 
 
Anxiety is not currently directly linked to HE (Telles-Correia et al., 2015) and may be 
difficult to separate from the psychological complexities inherent in any chronic 
disease, including chronic liver disease (Haag et al., 2008, Polis and Fernandez, 
2015, Zhang et al., 2016). Nevertheless, an association with anxiety behaviour in 
animals treated with TAA and associated liver damage demonstrates a cognitive 
disturbance in these animals and is suggestive of some level of HE. 
 
4.4.4.3 Y-Maze 
There was no difference between the groups seen in the Y-maze in the present 
study. This is apparently at odds with previous research that has suggested deficits 
in spatial awareness as measured by a Y-maze using a similar method of TAA-
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induced liver failure as used here albeit in rats (Ding et al., 2015) as well as in a plus-
maze (Mendez et al., 2008). Ding and colleagues treated animals with TAA then 
selected the animals as having mHE based on their performance in the Y-maze such 
that only animals that had received TAA and also had a behavioural deficit were 
included in their study (Ding et al., 2015). Clearly there was variation in 
performance in the Y-maze in the present study with some animals in all groups 
scoring lower, however as variation was similar across all groups it seemed 
inappropriate to stratify the groups based on performance as carried out by Ding et 
al. 
 
Taken together with the existing literature it appears there is an acute motor deficit 
in TAA-models which is not present at later time-points. With chronic TAA 
administration an anxiety component develops with no associated motor or 
working memory impairment. 
 
4.4.5 An animal model of Type C HE 
The goal here was to establish a model of Type C HE that satisfied Butterworth and 
Norenberg’s criteria (Butterworth et al., 2009). Additionally, as clinical HE is most 
likely a multi-factorial disease, multiple exposures were used here to test if 
combinational models may be more appropriate. Each of these criteria are 
addressed below: 
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4.4.5.1 Chronic liver disease with portal-systemic shunting 
Chronic liver disease was seen in TAA-treated animals with hepatomegaly, 
nodularity of the liver and elevation of transaminases. Microscopic pathology was 
not performed here to confirm a pathological diagnosis of cirrhosis but is part of 
ongoing work characterising the liver damage in this model. Notwithstanding a 
pending pathological diagnosis, there is reasonable evidence here to suggest 
chronic liver disease was present in TAA-treated animals. One limitation with the 
TAA model used here however is the acuity of the liver pathology in such models. 
Even low doses of TAA such as those used here can induce liver pathology in days 
(Avraham et al., 2011).  In the absence of acute signs of liver failure, such as coma, 
it appears that most animals did experience a chronic liver insult. 
 
It is not possible to comment on portal-systemic shunting specifically from the 
present work. The assessment of portal-systemic shunting requires specialised 
techniques such as quantification of 51Chrome microspheres (Stauber et al., 1992, 
Van de Casteele et al., 2001) or single photon imaging (Van Steenkiste et al., 2010). 
This was beyond the scope of this project. 
 
4.4.5.2 Range of symptoms of encephalopathy from mHE to coma 
Chronic TAA administration produced a subtle behavioural deficit with increased 
levels of anxiety measured by the Open-Field test. Notably, anxiety phenotypes 
were only evident in two parameters of the Open-Field Test. There were no motor 
deficits or working memory dysfunction in the Y-maze. Additionally, there were 
animals in the TAA, OH + TAA and HFD + TAA groups that became comatose and 
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died shortly after administration of TAA. This may represent an acute, severe form 
encephalopathy, although it is unclear why these particular animals were affected. 
 
4.4.5.3 Alzheimer type II astrocytosis at coma stages of encephalopathy 
Alzheimer type II astrocytosis is associated with severe forms of chronic HE in 
humans. Although a small number of animals died shortly after the first TAA 
injection, this likely reflected development and consequent death as a result of ALF 
and accordingly these animals were not used in analyses. As the majority of TAA-
treated animals here were likely to have mHE, at worst, the At2a were not 
considered useful as a diagnostic aid and consequently not investigated here. 
Human studies of HE have shown a decrease in the astrocytic marker GFAP (Kimura 
and Budka, 1986, Kretzschmar et al., 1985, Sobel et al., 1981) and so GFAP was used 
as a surrogate for At2a here. There was no difference in GFAP expression in the DG 
although functional differences in GFAP between mice and humans may complicate 
this result. In humans GFAP is considered a constitutive marker whereas in mice it 
may reflect more of an activation marker (Eng and Ghirnikar, 1994). To address 
Alzheimer type II astrocytosis in this model future studies may use a longer course 
of TAA injections or a pre-determined end-point of coma. 
 
4.4.5.4 Hyperammonaemia, increased brain ammonia/glutamine 
A major limitation to the confirmation of chronic HE was a lack of measures of 
cerebral and serum ammonia levels. This is despite multiple attempts to analyse 
brain ammonia levels using snap-frozen hemispheres as per previous reports 
(Dejong et al., 1993, Gomides et al., 2014, Jiang et al., 2009b) and using different 
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batches of a commercially available kit (Cat No AA0100. Sigma-Aldrich, St Louis 
USA). The reason for this kit being unsuccessful here remains unclear. Extensive 
optimisation was carried out however no signal was obtained even using the kit 
provided standard ammonia solutions strongly suggesting that the kits themselves 
were faulty.  
 
Taken together, this model demonstrates evidence for liver damage and an 
associated behavioural deficit, namely anxiety in TAA-treated animals. This provide 
preliminary evidence for these animals experiencing some form of HE. In terms of 
combination treatments with HFD and OH there was no clear interaction present in 
this model suggesting a synergistic effect of alcohol use or NASH with chronic liver 
disease in terms of behaviour. 
 
4.4.6 Neuropathology 
 
4.4.6.1 Iba1 staining 
HE is generally regarded as primarily a disease of astrocytes yet microglial 
activation is also a reported feature of human HE (Dennis et al., 2014, Gorg et al., 
2013, McMillin et al., 2014, Zemtsova et al., 2011). Furthermore, work reported 
here in chapter 3 showed both microglial dystrophy and proliferation in subsets of 
chronic alcoholics with HE (Dennis et al., 2014). Accordingly, this study attempted 
to replicate the microglial changes seen in humans in an animal model of chronic 
HE. 
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Models of Type A HE using end-to-side portacaval anastomosis (Jiang et al., 2009c, 
Jiang et al., 2009a), hyperammonemia (Hernandez-Rabaza et al., 2016) 
azoxymethane (McMillin et al., 2014, Rangroo Thrane et al., 2012) and TAA 
(Faleiros et al., 2014) have all demonstrated microglial activation however these are 
in the setting of ALF. An important aim of this study was differentiating between 
the acute phase microglial response and a more chronic response that occurs in 
humans with chronic liver injury (Dennis et al., 2014). Given a mild behavioural 
phenotype and significant liver pathology it is reasonable to suggest that TAA-
treated animals experienced some form of HE throughout the experiment. 
Nevertheless, no microglial abnormalities were detected in the TAA groups with 
either of the pathological screening tools used here.  
 
An important distinction as mentioned above is differentiating between the acute 
microglial response and if there is a more chronic activation occurring. Graeber and 
Streit have proposed that when a microglial cell is exposed to a chronic activating 
insult/stimulus (as hypothesised to be the case in the setting of chronic liver 
disease) it will ultimately undergo dystrophy and be unable to continue carrying out 
its neuroprotective functions (Graeber and Streit, 2010). Dystrophy is a relatively 
new concept in humans and there has been no published evidence of such a 
process in mice. 
 
Acute microglial activation is usually a dramatic and easily recognisable event and 
similarly extensive microglial dystrophy is also identifiable when severe. The time 
frame between these two events however is presumably long and whether a 
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microglial cell undergoing subtle shifts in response to chronic activation is 
identifiable pathologically is an area of debate. 
 
Such subtler changes in microglial phenotype cannot be ruled out using Iba1 
immunohistochemistry alone. To fully classify the activation state of microglia other 
markers are required such as CD11b/c (early activation (Marshall et al., 2016, 
Hynes, 1992, Morioka et al., 1992, Graeber et al., 1994)), CD68 (phagocytic 
lysosomes indicative of phagocytic activity (Bauer et al., 1994)), and MHC class II 
molecules (T-cell activation (Raivich et al., 1999)). A full battery of 
immunohistochemical markers would allow a more complete understanding of the 
functions of microglia at a point in time and can give indications on the activation 
state and infer functions of a particular cell. As with human tissue, different 
antibodies are differentially susceptible to fixation (Lyck et al., 2008) and notably 
reliable CD11b and CD68 staining has only been shown in rat tissue that has 
undergone two hours of immersion fixation with paraformaldehyde (Marshall et al., 
2016, Marshall et al., 2013). Despite considerable efforts with a variety of antigen 
retrieval techniques no staining with either CD11b or CD68 was achieved in the 
tissue used in this study and is likely due to the longer, 24-hour fixation period. 
 
In contrast to TAA-treated animals, there was evidence of microglial activation in 
the prefrontal cortex of the OH animals. Increased Iba1 expression in the prefrontal 
cortex of animals receiving OH was interesting particularly given no accompanying 
behavioural deficit in these animals. As such changes were not seen in TAA-treated 
animals and liver damage was minimal in OH-only animals it is likely this is due to 
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the direct toxic effects of alcohol. It is also interesting to note that the prefrontal 
cortex is one of the few areas that display neuronal loss in the brain of chronic 
alcoholics (Kril et al., 1997b). Although the ethanol dose was low throughout the 
experiment it may have been sufficient to have neurotoxic effects, with subsequent 
microglial activation. Consistent with this, chronic ethanol exposure in adolescent 
mice is associated with low level microglial activation (McClain et al., 2011). 
 
Taken together this study provides a useful primary microglial screen that 
demonstrated no gross changes in the HE models. This screen cannot rule out more 
subtle shifts in microglial activation state and further studies are warranted with a 
broader scope of microglial markers given the mild behavioural phenotype seen in 
TAA-treated animals and the microglial changes evident in human HE as well as ALF 
models.  
 
4.4.6.2 GFAP staining 
HE is considered primarily an astrocytic disease with the main pathological changes 
in humans being that of At2a changes and decreased expression of GFAP (Kril et al., 
1997a). Here there was no changes in GFAP expression in the DG of any group. 
GFAP is an intermediate filament protein and is a widely used marker of astrocytes 
(Pekny and Pekna, 2004) however recently it appears that GFAP labels reactive and 
protoplasmic astrocytes and there are a large number of mature astrocytes are not 
labelled by GFAP (Sofroniew, 2009, Sofroniew and Vinters, 2010). Notably, a 
decrease in GFAP expression as seen in human HE may well reflect a shift in 
astrocyte activity rather than a change in total cell number per se. Other markers 
 167 
such as aldehyde dehydrogenase L1 have recently been suggested as a more 
appropriate pan-astrocytic marker (Serrano-Pozo et al., 2013). Nevertheless, it is 
important to also note the differences in the composition of the mouse brain 
compared to the human brain. The mouse consists of very little WM restricted 
mostly to the corpus callosum as opposed humans who have extensive WM tracts 
throughout the brain. Accordingly, there may not be direct translation of the 
astrocyte changes seen in human HE to animal models and no such evidence was 
seen in this study. 
 
4.5 Conclusions 
 
Chronic administration of i.p. TAA induces macroscopic liver pathology, elevations 
of transaminases and an associated behavioural phenotype reflective of anxiety. 
There were no changes in Iba1 or GFAP immunoreactivity in a number of brain 
regions and addition of HFD or OH or both had no cumulative effects with TAA. To 
fully elucidate and understand the glial changes occurring in HE further work is 
warranted towards developing this model of chronic HE. Specifically, given the 
complexity and little apparent effect of HFD and OH this model could be refined to 
use only TAA and administer a longer course to more accurately model chronic HE 
in the setting of cirrhosis. This would be combined with additional phenotyping 
including histopathological examination of the livers, blood and brain ammonia 
measurements and profiling with additional microglia markers such as CD68. 
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5 General Discussion 
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This thesis set out to expand understanding around the pathogenesis of HE, 
particularly with regards to neuropathological changes. Previous work in this 
laboratory had identified that cell proliferation in the adult human brain is poorly 
understood in both normal and disease states. Accordingly, a general objective of 
this thesis was to provide clarity on cell proliferation in the normal brain as well as a 
specific focus in HE. 
 
In particular, the aims of this thesis were: 
 
1. To quantify the level of adult neurogenesis in the SVZ and SGZ of 
postmortem human brain. 
2. To investigate cell proliferation in the neurogenic niches of chronic 
alcoholics with HE. 
3. To develop a model of chronic HE that has similar neuropathological 
changes to those seen in chronic alcoholics with HE. 
 
In terms of Aim 1, Chapter 2 reported a marked decline in markers of neurogenesis 
in the SVZ and SGZ with age in postmortem human brain tissue (Dennis et al., 
2016). Importantly this work also demonstrated that all proliferating cells in the 
neurogenic niches in individuals older than three years were microglia. This 
descriptive study of cell proliferation in the human neurogenic niches provided 
much needed clarity to a controversial area by means of a systematic approach to 
both niches concurrently using a host of commonly used markers of neurogenesis 
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and proliferation. Given its exciting potential therapeutic implications, significant 
research effort has been poured into exploring the role of neurogenesis in disease 
states. Prior to examining disease states however it was crucial to have a 
comprehensive understanding of physiological processes in the normal situation.  
 
Chapter 3 describes the widespread microglial proliferation throughout the brains 
of a subset of chronic alcoholics with HE (Dennis et al., 2014). Furthermore, in the 
cases without microglial proliferation there was microglial dystrophy which 
correlated with neuronal loss in the superior frontal gyrus. This work identified a 
role for microglia in the disease process of HE however it remained unclear whether 
these changes reflected a mechanistic process driving pathological changes or a 
protective response to a currently unrecognised insult. Studies using human brain 
tissue are extremely valuable and offer a snapshot of the brain of patients suffering 
from a disease such as HE. A caveat is known and unknown confounders and co-
morbidities inherent to human studies. To understand whether the microglial 
changes seen in human HE were beneficial or deleterious and, or whether 
proliferation and dystrophy were temporally related to the course of the disease, 
an animal model of HE was required. 
 
Chapter 4 describes a mouse model of chronic HE using the hepatotoxin TAA, in 
combination with other common causative agents of liver damage leading to HE; 
alcohol and HFD. Previous attempts to model this disease had focused on acute HE 
(Avraham et al., 2011, Ding et al., 2015, Faleiros et al., 2014, Farjam et al., 2012, 
Gomides et al., 2014, McMillin et al., 2014, Miquel et al., 2010, Miranda et al., 
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2010, Rangroo Thrane et al., 2012) but no widely-accepted model of chronic HE had 
been described. This work demonstrated a mild behavioural phenotype and liver 
damage in TAA-treated animals but no obvious microglial changes.  
 
Taken together this thesis has shown that cell proliferation occurs at a low level in 
the normal human brain and is predominantly microglial. Microglial turnover can be 
influenced by disease states such as HE, but whether microglial proliferation and 
activation is beneficial or deleterious remains unknown. 
 
5.1 Cell proliferation in the human brain 
The differences between the human and rodent brain are substantial, as evidenced 
through our vast differences in cognition and intelligence. As such when using 
animal models to extrapolate to human diseases these differences need to be 
quantified. One such example is cell proliferation. Until as recently as 70 years ago, 
the CNS was considered a post-mitotic organ (Altman, 1963), however there is now 
evidence of proliferation of neurons (Doetsch et al., 1999), oligodendrocytes 
(Dawson et al., 2003), astrocytes (Horner et al., 2000) and microglia (Marshall et al., 
2016, Nixon and Crews, 2004) in lower mammals.  
 
In particular, the extent of cell proliferation outside the neurogenic niches in 
normal adult human brain was largely unknown. Chapter 3 provides the first 
definitive evidence of microglial proliferation in the normal human brain, that is co-
localisation of a proliferative marker (Ki67) with a constitutive microglial marker 
(Iba1) (Dennis et al., 2014). Since then, further studies have confirmed microglial 
 172 
proliferation occurs at a low level in the normal adult human brain (Olmos-Alonso 
et al., 2016). Microglial proliferation is generally considered synonymous with 
activation and although these two processes can occur together they can also occur 
independent to the other. 
 
Contrastingly, the role of adult neurogenesis in normal physiological function and 
therefore its probability of influencing pathological states appears negligible given 
the paucity of evidence for persistent neurogenesis in the adult human brain 
(Dennis et al., 2016, Sanai et al., 2011). When cell proliferation is seen in 
neurogenic niches, it is often assumed to be of a neuronal origin however this 
conclusion is often made with insufficient evidence (Curtis et al., 2007b, Curtis et 
al., 2003). This thesis shows the necessity of careful cell phenotyping, most notably 
it demonstrates that microglia are the only proliferating cells present in the adult 
human neurogenic niches and the vast majority of proliferating cells outside of 
these niches (Dennis et al., 2016). Although it is possible that quiescent neural stem 
cells remain clarification of this would require the use of additional markers 
including GFAP. Indeed, ex vivo studies of neurogenic niches have consistently 
demonstrated neurosphere production in culture (Kirschenbaum et al., 1994, 
Pincus et al., 1998, Roy et al., 2000a, Roy et al., 2000b) These data remain 
consistent with results reported here if stem cell quiescence is an active process 
relying on intrinsic factors in the adult human brain. Finally, the level of microglial 
proliferation in the neurogenic niches was similar to adjacent regions of the 
caudate nucleus and distal cortical areas such as the superior frontal gyrus. One 
caveat here is that the absence of a specific cell marker for oligodendrocyte 
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precursor cells, meant that proliferation of this glial subtype may have been 
underestimated.  
 
The brain is a dynamic microenvironment and although the majority of cells are 
considered differentiated, microglia retain their ability to proliferate and indeed do 
turnover, albeit at very low rate in the normal human brain. Microglia, and their 
potential proliferation, should be considered in pathological contexts and further 
understanding of these roles may well present promising therapeutic avenues 
including and beyond diseases such as HE.  
 
5.2 Microglia and proliferation in HE 
HE is a complex disorder with an unknown pathogenesis. This thesis identified that 
microglia show dynamic changes throughout the disease process. This is consistent 
with other work identifying upregulation of genes associated with proliferation in 
patients with HE (Gorg et al., 2013, Zemtsova et al., 2011) as well as microglial 
activation (Gorg et al., 2013, Zemtsova et al., 2011). 
 
Microglia are an important homeostatic cell in the CNS and their functions including 
activation are tightly controlled, measured responses. The long-standing dogma of 
microglial activation as a harmful event is rapidly being overturned with microglial 
activation now being viewed as a beneficial response but with the capacity to 
become unregulated and consequently harmful over time (Graeber, 2010). 
Microglia are constantly sampling their territories (Nimmerjahn et al., 2005) and 
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have an evolving array of physiological roles including the highly specialised 
synaptic stripping (Trapp et al., 2007, Wake et al., 2009). 
 
Indeed, a common argument with important implications into the pathogenesis and 
potential treatment of HE is whether changes from a ramified state of microglia 
reflect a protective or harmful response. A seminal study by Streit et al. using 
postmortem human brain tissue from patients with Alzheimer’s disease and Down 
Syndrome demonstrated that the appearance of Aß pathology preceded microglial 
activation while neuronal loss was not seen unless microglial dystrophy was also 
present (Streit et al., 2009). This importantly showed that microglia are unlikely to 
be driving the disease and that in fact neuronal loss occurs only once microglial cells 
and presumably their protective functions are lost. A similar neuropathology was 
described in chronic alcoholics with HE in chapter 3 and may well reflect a 
protective role for microglia and HE. Graeber and Streit hypothesise that acute 
microglial activation is largely a beneficial process in response to a threat to the 
microenvironment however persistent activation can lead to microglial dystrophy 
and a loss of their protective functions and consequently neuronal damage and 
death (Graeber and Streit, 2010). 
 
Undoubtedly microglia have a role in the disease process of HE and may well 
provide a therapeutic avenue for this debilitating disease. Given the chronic nature 
and complexity of HE, with liver dysfunction, elevated ammonia and manganese 
levels, cytokine (Dennis et al., 2014, Jain et al., 2013, Shawcross et al., 2004, Wright 
et al., 2007b, Wunsch et al., 2013) and neutrophil derangements (Shawcross et al., 
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2010) all likely contributing to its pathogenesis it is unclear what is triggering 
microglial proliferation. Understanding what is the initial trigger in the chain of 
events leading to microglial activation, proliferation and dystrophy may well prove 
key to unlocking the key event in HE. 
 
To extrapolate causal links animal models of diseases are useful. Given the 
microglial changes seen in HE are likely a result of a long-standing chronic insult a 
model reflecting this chronicity is required. This thesis highlighted the difficulty of 
accurately modelling a chronic form of HE. A consistent problem with all chronic 
human brain diseases is how to model time and HE in chronic alcoholics is no 
exception with clinical signs manifesting after the patient has endured possibly 
decades of mHE. Most HE models to date have replicated the acute scenario 
associated with liver failure, a key, yet mostly terminal event, in the absence of liver 
transplant. HE hospital admissions related to chronic alcoholism are continually 
rising (Nguyen et al., 2016) but NASH is also an increasing burden and what with 
the current obesity epidemic (Cameron et al., 2003, Colagiuri et al., 2010) there 
may in the future be a significant intersection of these two risk factors promoting 
the prevalence of HE. 
 
Perhaps the most problematic aspect is, in the absence of a true phenocopy, 
deciding which feature of the human disease is most important to a ‘useful’ model 
whether it be the presence of cirrhosis to ammonia levels or astrocytic changes. 
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5.3 Future directions 
This thesis has offered a number of novel insights into the dynamics of cell 
proliferation in the adult human brain with a particular focus on the role of 
microglial proliferation in HE. It therefore opens up a number of avenues for future 
work. 
 
Despite some groups suggesting adult neurogenesis in the human brain may still be 
a physiologically significant process and indeed contribute to certain neurological 
diseases (Marucci, 2016, Spalding et al., 2013) there is now a large body of evidence 
suggesting that neurogenesis in the adult human brain is negligible and unlikely to 
be functionally relevant (Dennis et al., 2016, Lazic et al., 2014, Sanai et al., 2011). 
What remains of interest biologically is why there is such a marked difference in 
adult neurogenesis between humans and other mammals. Additionally, the 
mechanism by which neurogenesis “turns off” in the infant human brain is 
unknown and future work could be targeted at identifying what controls this and if 
so whether it is feasible to manipulate this redundant embryological process as a 
way to treat neurodegenerative disorders.  
 
The finding of microglial proliferation, activation and dystrophy in chronic alcoholics 
with HE is a novel finding and beyond elucidating what is driving these changes the 
implications of these changes on other microglial functions are interesting to 
consider. One particular area is that of synaptic stripping, a relatively new role for 
microglia. Unpublished data using ground state depletion microscopy has suggested 
that microglial cells in cases with widespread proliferation have decreased synaptic 
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uptake compared to control (Fok S, Dennis CV, Graeber M et al., unpublished 
findings). If microglial cells shift their function to a protective role in HE they may 
well neglect their physiological functions such as synaptic stripping. Without the 
constant surveillance of synapses by microglia, exuberant synapses may persist and 
lead to neurological derangements that could explain the clinical presentation of 
HE. Future work could accordingly be targeted at examining synaptic proteins in HE 
as well as other components of the microglial-synaptic pathway such as the 
complement system in the brain (Stevens et al., 2007). 
 
Finally, a reliable model of chronic Type C HE remains elusive. The work presented 
in Chapter 4 has further assisted in guiding efforts towards developing this chronic 
model. This experiment was much longer than the majority of previous work using 
hepatotoxins however eight weeks is still a relatively short time course relative to 
the human disease. A major concern here prior to the experiment was the lethality 
of eight weeks of TAA injections however given they were tolerated well, future 
work with an extended time course are warranted. Additionally, given no changes 
were seen in the multiple exposure groups, restricting to a more basic model of 
TAA alone would be beneficial along with optimisation of cerebral ammonia assays. 
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5.4 Conclusions 
At the beginning of this work: 
 
1. Neurogenesis in human brain was ‘proven’. 
 
2. HE was considered primarily an astrocytic disease. 
 
3. Microglial proliferation was presumed to occur in the adult human brain but 
never described. 
 
4. There were no accurate models of type C HE. 
 
Cell proliferation is now unequivocally proven to occur in the adult human brain 
and by far the most common cell to undergo proliferation are microglia but this is 
at a very low level under normal conditions. Neurogenesis however is exceptionally 
rare and while there remains a theoretical potential for it to be upregulated, given 
the evidence presented here, it seems unlikely to play a major role in the 
pathogenesis of chronic brain diseases. 
 
The pathogenesis of HE remains elusive but it is now clear that microglial changes 
occur in the disease process. The reason for the prolific microglial response in a 
subset of HE brains is unknown as is how microglial dystrophy fits temporally into 
the disease. Yet these findings have provided novel insights into a largely unknown 
and debilitating disease. Notwithstanding the novelty of microglial proliferation, it 
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was the loss of microglia through a dystrophic process that appeared more 
important in HE. Given their support functions for neurons, finding mechanisms 
that prevent microglial demise could open a new avenue for not only HE but other 
neurodegenerative diseases in general. 
 
Overall this thesis has expanded our knowledge of the physiology of microglial in 
the human brain, a cell type that is rapidly becoming recognised as a central player 
in maintaining the brain microenvironment. It has offered novel insights into the 
pathogenesis of HE and provided definition of the neuropathology of the disease. 
The precise mechanism of HE remains unknown but this thesis has provided an 
important step into directing future work into unravelling this debilitating disease. 
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